International Stem Cell (ISCO) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'ISCO	'
Entity Registrant Name	'International Stem Cell CORP	'
Entity Central Index Key	'0001355790	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	213,590,669

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (2014 Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Assets	'	'
Cash and cash equivalents	$748,000	$2,243,000
Accounts receivable, net of allowance for doubtful accounts of $19 at June 30, 2014 and December 31, 2013	406,000	306,000
Inventory, net	1,470,000	1,369,000
Prepaid expenses and other current assets	539,000	658,000
Restricted cash	50,000	50,000
Total current assets	3,213,000	4,626,000
Property and equipment, net	847,000	830,000
Intangible assets, net	2,522,000	2,250,000
Deposits and other assets	33,000	33,000
Total assets	6,615,000	7,739,000
Liabilities, Redeemable Preferred Stock and Stockholders' Deficit	'	'
Accounts payable	798,000	532,000
Accrued liabilities	960,000	1,290,000
Deferred revenue	0	3,000
Related party payable	31,000	21,000
Advances	250,000	250,000
Fair value of warrant liability	'	4,925,000
Total current liabilities	2,039,000	7,021,000
Commitments and contingencies	'	'
Stockholders' Deficit	'	'
Common stock, $0.001 par value, 600,000,000 and 300,000,000 shares authorized, 213,590,669 and 151,175,053 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	214,000	151,000
Additional paid-in capital	87,537,000	77,897,000
Accumulated deficit	-88,116,000	-82,271,000
Total stockholders' deficit	-365,000	-4,223,000
Total liabilities, redeemable preferred stock and stockholders' deficit	6,615,000	7,739,000
Series G Preferred Stock [Member]	'	'
Liabilities, Redeemable Preferred Stock and Stockholders' Deficit	'	'
Convertible Redeemable Series G Preferred stock, $0.001 par value, 5,000,000 shares authorized, issued and outstanding at June 30, 2014 and December 31, 2013, liquidation preference of $5,000 at June 30, 2014 and December 31, 2013	4,941,000	4,941,000
Series D Preferred Stock [Member]	'	'
Stockholders' Deficit	'	'
Preferred stock	'	'
Series B Preferred Stock [Member]	'	'
Stockholders' Deficit	'	'
Preferred stock	'	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (2014 Unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts receivable	$19	$19
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	600,000,000	300,000,000
Common stock, shares issued	213,590,669	151,175,053
Common stock, shares outstanding	213,590,669	151,175,053
Series G Preferred Stock [Member]	'	'
Convertible Redeemable Preferred stock, par value	$0.00	$0.00
Convertible Redeemable Preferred stock, shares authorized	5,000,000	5,000,000
Convertible Redeemable Preferred stock, shares issued	5,000,000	5,000,000
Convertible Redeemable Preferred stock, shares outstanding	5,000,000	5,000,000
Convertible Redeemable Preferred stock, liquidation preference	5,000	5,000
Series D Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50	50
Preferred stock, shares issued	43	43
Preferred stock, shares outstanding	43	43
Liquidation preference	4,320	4,320
Series B Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	300,000	300,000
Preferred stock, shares outstanding	300,000	300,000
Liquidation preference	$412	$403

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues	'	'	'	'
Product sales	$1,588,000	$1,457,000	$3,237,000	$2,742,000
Total revenue	1,588,000	1,457,000	3,237,000	2,742,000
Expenses	'	'	'	'
Cost of sales	409,000	329,000	848,000	663,000
Research and development	1,411,000	974,000	2,369,000	1,695,000
Selling and marketing	679,000	679,000	1,348,000	1,191,000
General and administrative	1,332,000	1,665,000	2,980,000	3,097,000
Total expenses	3,831,000	3,647,000	7,545,000	6,646,000
Loss from operating activities	-2,243,000	-2,190,000	-4,308,000	-3,904,000
Other income (expense)	'	'	'	'
Change in fair value of warrant liability	1,271,000	'	1,894,000	'
Warrant exchange inducement expense	-3,445,000	'	-3,445,000	'
Miscellaneous expense	'	-18,000	'	-20,000
Interest expense	-1,000	-1,000	-2,000	-2,000
Sublease income	8,000	9,000	16,000	13,000
Total other income (expense), net	-2,167,000	-10,000	-1,537,000	-9,000
Loss before income taxes	-4,410,000	-2,200,000	-5,845,000	-3,913,000
Provision for income taxes	'	'	'	'
Net loss	-4,410,000	-2,200,000	-5,845,000	-3,913,000
Net loss applicable to common stockholders	($4,410,000)	($2,200,000)	($5,845,000)	($3,913,000)
Net loss per common share-basic and diluted	($0.03)	($0.02)	($0.04)	($0.04)
Weighted average shares-basic and diluted	170,632	112,410	162,108	108,013

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Deficit (USD $)	Total	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Convertible Redeemable Preferred Stock [Member]	Common Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data, unless otherwise specified	USD ($)			Series G Preferred Stock [Member]	USD ($)	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	USD ($)	USD ($)
				USD ($)			USD ($)	USD ($)
Beginning balance at Dec. 31, 2012	($1,758)	'	'	$4,941	$87	'	$2	$0	$69,945	($71,792)
Beginning balance, shares at Dec. 31, 2012	'	'	'	5,000,000	87,389,000	300,000	2,000,000	0	'	'
Issuance of common stock from conversion of Series C preferred stock	'	'	'	'	8	'	-2	'	-6	'
Issuance of common stock from conversion of Series C preferred stock, shares	'	'	'	'	8,000,000	'	-2,000,000	'	'	'
Issuance of common stock	'	'	'	'	'	'	'	'	'	'
For cash, net of issuance costs of $178 in 2013 and $169 in 2014	3,381	'	'	'	38	'	'	'	3,343	'
For cash, net of issuance costs of $178 in 2013 and $169 in 2014, shares	'	'	'	'	37,991,000	'	'	'	'	'
For services	240	'	'	'	1	'	'	'	239	'
For services, shares	'	'	'	'	840,000	'	'	'	'	'
From exercises of warrants, net of commissions of $98	2,700	'	'	'	17	'	'	'	2,683	'
From exercises of warrants, net of commissions of $98, shares	'	'	'	'	16,955,000	'	'	'	'	'
Stock-based compensation	1,693	'	'	'	'	'	'	'	1,693	'
Net loss	-10,479	'	'	'	'	'	'	'	'	-10,479
Ending balance at Dec. 31, 2013	-4,223	'	'	4,941	151	'	'	0	77,897	-82,271
Ending balance, shares at Dec. 31, 2013	'	'	'	5,000,000	151,175,000	300,000	'	0	'	'
Issuance of common stock	'	'	'	'	'	'	'	'	'	'
For cash, net of issuance costs of $178 in 2013 and $169 in 2014	2,469	'	'	'	17	'	'	'	2,452	'
For cash, net of issuance costs of $178 in 2013 and $169 in 2014, shares	'	'	'	'	17,033,000	'	'	'	'	'
For services	85	'	'	'	1	'	'	'	84	'
For services, shares	'	'	'	'	717,000	'	'	'	'	'
For warrant exchange, net of issuance costs of $49	6,428	'	'	'	45	'	'	'	6,383	'
For warrant exchange, net of issuance costs of $49, shares	'	'	'	'	44,666,000	'	'	'	'	'
Stock-based compensation	721	'	'	'	'	'	'	'	721	'
Net loss	-5,845	'	'	'	'	'	'	'	'	-5,845
Ending balance at Jun. 30, 2014	($365)	'	'	$4,941	$214	'	'	$0	$87,537	($88,116)
Ending balance, shares at Jun. 30, 2014	'	'	'	5,000,000	213,591,000	300,000	'	0	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Statement Of Stockholders Equity [Abstract]	'	'
For cash, issuance costs	$169	$178
From exercise of warrants, commissions	'	98
Warrant exchange, issuance costs	$49	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities	'	'
Net loss	($5,845,000)	($3,913,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	234,000	231,000
Stock-based compensation expense	721,000	849,000
Common stock issued for services	85,000	137,000
Change in fair value of warrant liability	-1,894,000	'
Warrant exchange inducement expense	3,445,000	'
Allowance for doubtful accounts	'	22,000
Allowance for inventory obsolescence	22,000	8,000
Loss on disposal of fixed assets	'	16,000
Impairment of intangible assets	36,000	19,000
Changes in operating assets and liabilities	'	'
(Increase) decrease in accounts receivable	-100,000	-203,000
(Increase) decrease in inventory	-123,000	-179,000
(Increase) decrease in prepaid assets and other assets	119,000	-207,000
Increase (decrease) in restricted cash	'	-50,000
Increase (decrease) in deposit	'	-12,000
Increase (decrease) in accounts payable	266,000	-226,000
Increase (decrease) in accrued liabilities	-330,000	659,000
Increase (decrease) in deferred revenue	-3,000	-61,000
Increase (decrease) in related party payable	10,000	17,000
Net cash used in operating activities	-3,357,000	-2,893,000
Investing activities	'	'
Purchases of property and equipment	-218,000	-11,000
Proceeds from sale of property and equipment	1,000	'
Payments for patent licenses and trademarks	-341,000	-362,000
Net cash used in investing activities	-558,000	-373,000
Financing activities	'	'
Proceeds from issuance of common stock	2,638,000	3,289,000
Payment of offering costs	-218,000	-23,000
Net cash provided by financing activities	2,420,000	3,266,000
Net increase (decrease) in cash and cash equivalents	-1,495,000	'
Cash and cash equivalents, beginning of period	2,243,000	654,000
Cash and cash equivalents, end of period	748,000	654,000
Supplemental disclosure of cash flow information	'	'
Cash paid for interest	2,000	2,000
Warrant liability reclassified to equity upon warrant exchange	$3,031,000	'

Organization_and_Significant_A

Organization and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Organization and Significant Accounting Policies	'
	1. Organization and Significant Accounting Policies
	Business Combination and Corporate Restructure
	BTHC III, Inc. (“BTHC III” or the “Company”) was organized in Delaware in June 2005 as a shell company to effect the reincorporation of BTHC III, LLC, a Texas limited liability company. On December 28, 2006, the Company effected a Share Exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation, a California corporation (“ISC California”). After giving effect to the Share Exchange, the stockholders of ISC California owned 93.7% of issued and outstanding shares of common stock. As a result of the Share Exchange, ISC California is now the wholly-owned subsidiary, though for accounting purposes it was deemed to have been the acquirer in a “reverse merger.” In the reverse merger, BTHC III is considered the legal acquirer and ISC California is considered the accounting acquirer. On January 29, 2007, the Company changed its name from BTHC III, Inc. to International Stem Cell Corporation.
	Lifeline Cell Technology, LLC (“LCT”) was formed in the State of California on August 17, 2001. LCT is in the business of developing and manufacturing purified primary human cells and optimized reagents for cell culture. LCT’s scientists have used a technology, called basal medium optimization, to systematically produce products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. LCT distinguishes itself in the industry by having in place scientific and manufacturing staff with the experience and knowledge to set up systems and facilities to produce a source of consistent, standardized, non-human animal protein free cell products, some of which are suitable for FDA approval.
	On July 1, 2006, LCT entered into an agreement among LCT, ISC California and the holders of membership units and warrants. Pursuant to the terms of the agreement, all the membership units in LCT were exchanged for 20,000,000 shares of ISC California Common Stock and for ISC California’s assumption of LCT’s obligations under the warrants. LCT became a wholly-owned subsidiary of ISC California.
	Lifeline Skin Care, Inc. (“LSC”) was formed in the State of California on June 5, 2009 and is a wholly-owned subsidiary of ISC California. LSC develops, manufactures and markets cosmeceutical products, utilizing an extract derived from the Company’s human parthenogenetic stem cell technologies.
	Going Concern
	The Company needs to raise additional working capital. The timing and degree of any future capital requirements will depend on many factors. Currently, the Company’s burn rate is approximately $560,000 per month, excluding capital expenditures and patent costs averaging $93,000 per month. There can be no assurance that the Company will be successful in maintaining its normal operating cash flow, and that such cash flows will be sufficient to sustain the Company’s operations through 2014. Based on the above, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements were prepared assuming that the Company is a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
	Management’s plans in regard to these matters are focused on managing its cash flow, the proper timing of its capital expenditures, and raising additional capital or financing in the future. In December 2013, the Company filed a registration statement with the Securities Exchange Commission (the “SEC”), which allows the Company to sell up to $10,250,000 of common stock to Lincoln Park Capital Fund, LLC (“Lincoln Park”) from time to time through January 2017 at the Company’s discretion. The registration statement was declared effective on January 13, 2014. However, the Company cannot predict the timing or amount of any funds that it may actually receive, and as part of the June 2014 warrant exchange transaction discussed below, the Company agreed that until September 14, 2014 it would not issue additional shares in capital raising transactions other than in private placements to its officers and directors. During the six months ended June 30, 2014, to obtain funding for working capital purposes, the Company sold a total of 8,200,000 shares of common stock under the stock Purchase Agreement with Lincoln Park, raising approximately $1,588,000. For further discussion, see Note 6, Capital Stock.
	During the second quarter of 2014, the Company sold an additional 8,833,333 shares of common stock to the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors, Dr. Andrey Semechkin, and Dr. Ruslan Semechkin, Chief Scientific Officer and a director, for an aggregate of $1,050,000, as discussed in Note 6, Capital Stock.
	Basis of Presentation
	The Company is a biotechnology company focused on therapeutic and clinical product development with multiple long-term therapeutic opportunities and two revenue-generating subsidiaries with potential for increased future revenues. The Company was in the development stage from inception through the quarter ended September 30, 2013. During the quarter ended December 31, 2013, the Company exited the development stage based on a consistent, increasing revenue trend and more significant revenue generated from its two commercial businesses. The Company generated product revenues from the two commercial businesses of $6,147,000 for the year ended December 31, 2013. The Company currently has no revenue generated from its principal operations in therapeutic and clinical product development.
	The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q.
	These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to consolidated financial statements included in the annual report on Form 10-K of International Stem Cell Corporation and Subsidiaries for the year ended December 31, 2013. When used in these notes, the terms “Company,” “we,” “us,” or “our” mean International Stem Cell Corporation and all entities included in the unaudited condensed consolidated financial statements.
	In the opinion of management, the unaudited condensed consolidated financial information for the interim periods presented reflects all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the Company’s consolidated results of operations, financial position and cash flows. The unaudited condensed consolidated financial statements and the related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2013 included in the Company’s annual report on Form 10-K. Operating results for interim periods are not necessarily indicative of the operating results for any other interim period or an entire year.
	Principles of Consolidation
	The Company’s consolidated financial statements include the accounts of International Stem Cell Corporation and its subsidiaries after intercompany balances and transactions have been eliminated.
	Reclassification
	Certain amounts within the unaudited condensed consolidated statements of operations for the prior period have been reclassified to conform to the current period presentation. These reclassifications had no impact on the Company’s previously reported results of operations.
	Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
	Restricted Cash
	The Company is required to maintain $50,000 in a restricted certificate of deposit account in order to fully collateralize two revolving credit card accounts.
	Inventories
	Inventories are accounted for using the first-in, first-out (FIFO) method for LSC products, and specific identification method for LCT products. Inventory balances are stated at the lower of cost or market. Laboratory supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolescence and is adjusted accordingly.
	Accounts Receivable
	Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable primarily consist of trade accounts receivable from the sales of LCT’s products, timing of cash receipts by the Company related to LSC credit card sales to customers, as well as LSC trade receivable amounts related to spa and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to accounts receivable and reserves specific amounts if collectability is no longer reasonably assured. As of June 30, 2014 and December 31, 2013, the Company had an allowance for bad debt totaling $19,000.
	Property and Equipment
	Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over five years. The costs of major remodeling and leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the life of the asset.
	Intangible Assets
	Intangible assets consist of acquired research and development rights used in research and development, and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents. Patent or patent license amortization only begins once a patent license is acquired or a patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and patent licenses are recorded at cost and are amortized on a straight-line basis over the shorter of the lives of the underlying patents or the useful life of the license.
	Long-Lived Asset Impairment
	The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered, and at least annually. The Company considers assets to be impaired and writes them down to fair value if expected associated undiscounted cash flows are less than the carrying amounts. Fair value is the present value of the associated cash flows. The Company did not recognize material impairments on its long-lived assets during the three and six months ended June 30, 2014 and 2013.
	Product Sales
	The Company recognizes revenue from product sales at the time of shipment to the customer, provided no significant obligations remain and collection of the receivable is reasonably assured. If the customer has a right of return, the Company recognizes product revenues upon shipment, provided that future returns can be reasonably estimated. In the case where returns cannot be reasonably estimated, revenue will be deferred until such estimates can be made or the right of return has lapsed. LCT contributed 52% and 50% of total revenue during the six months ended June 30, 2014 and 2013, respectively. LSC contributed 48% and 50% of total revenue during the six months ended June 30, 2014 and 2013, respectively.
	Deferred Revenue and Allowance for Sales Returns
	The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed or determinable, and collectability is reasonably assured. However, the LSC products have a 30-day product return guarantee for website sales. The Company has estimated the historical rate of returns for the 30-day product return guarantee, which has remained consistent for the three and six months ended June 30, 2014 as compared to the years ended December 31, 2013 and 2012. At June 30, 2014 and December 31, 2013, the estimated allowance for sales returns was $10,000. At June 30, 2014 and December 31, 2013, net deferred revenue totaled $0 and $3,000, respectively.
	Cost of Sales
	Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products and include related direct materials, general laboratory supplies and allocation of overhead. Certain of the agreements under which the Company has licensed technology will require the payment of royalties based on the sale of its future products. Such royalties will be recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to developed technologies used in the Company’s products will be classified as a component of cost of sales to the extent such payments become due in the future.
	Research and Development Costs
	Research and development costs, which are expensed as incurred, are primarily comprised of costs and expenses for salaries and benefits associated with research and development personnel, overhead and occupancy, contract services, and amortization of license costs for technology used in research and development with alternative future uses.
	Stock-Based Compensation
	The Company recognized stock-based compensation expense associated with stock options and other stock-based awards in accordance with the authoritative guidance for stock-based compensation. The cost of a stock-based award is measured at the grant date based on the estimated fair value of the award, and is recognized as expense on a straight-line basis, net of estimated forfeitures over the requisite service period of the award. The fair value of stock options is estimated using the Black-Scholes option valuation model, which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. The fair value of restricted stock awards is based on the market value of our common stock on the date of grant.
	Fair Value Measurements
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
	Level 1		Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2	Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3	Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of June 30, 2014 (in thousands):
		Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents	$	5		$	5	$	—	$	—
	LIABILITIES:
	Warrants to purchase common stock	$	—		$	—	$	—	$	—
	The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2013 (in thousands):
		Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents	$	5		$	5	$	—	$	—
	LIABILITIES:
	Warrants to purchase common stock	$	4,925		$	—	$	—	$	4,925
	The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands):
		Warrants to purchase
		common stock
Beginning balance at December 31, 2012	$	—
Issuances of warrants		5,986
Exercise of warrants		(1,815	)
Adjustments to estimated fair value		754
Ending balance at December 31, 2013		4,925
Issuances of warrants		—
Exercise of warrants		—
Adjustments to estimated fair value		(1,894	)
Warrants exchanged for common stock		(3,031	)
Ending balance at June 30, 2014	$	—
Income Taxes
The Company accounts for income taxes in accordance with applicable authoritative guidance, which requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards.
Use of Estimates
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options, as well as the Monte-Carlo valuation method for certain warrants. Actual results could differ from those estimates.
Fair Value of Financial Instruments
The Company believes that the carrying value of its cash and cash equivalents, receivables, accounts payable and accrued liabilities as of June 30, 2014 and December 31, 2013 approximate their fair values because of the short-term nature of those instruments. The fair value of certain warrants was determined at each quarterly reporting date as necessary using the Monte-Carlo valuation methodology.
Income (Loss) Per Common Share
The computation of net loss per common share is based on the weighted average number of shares outstanding during each period. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. At June 30, 2014, there were 472,500 non-vested restricted stock awards, 20,236,077 vested and 7,082,333 non-vested stock options outstanding, and 7,762,500 warrants outstanding, which were convertible into 7,762,500 shares of common stock; and at June 30, 2013, there were 660,000 non-vested restricted stock awards, 16,916,733 vested and 6,846,560 non-vested stock options outstanding, and 9,462,500 warrants outstanding, which were convertible into 9,462,500 shares of common stock. These restricted stock awards, stock options and warrants were not included in the diluted loss per share calculation because the effect would have been anti-dilutive.
Comprehensive Income
Comprehensive income or loss includes all changes in equity except those resulting from investments by owners and distributions to owners. The Company did not have any items of comprehensive income or loss other than net loss from operations for the three and six months ended June 30, 2014 and 2013.
Registration Payment Arrangements
In accordance with applicable authoritative guidance, the Company is required to separately recognize and measure registration payment arrangements, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement. Such payments include penalties for failure to effect a registration of securities.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers.  The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective.  The new standard is effective for the Company on January 1, 2017.  Early application is not permitted.  The standard permits the use of either the retrospective or cumulative effect transition method.  The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures.  The Company has not yet selected a transition method nor has it determined the effect of the standard on it ongoing financial reporting.
In July 2013, the FASB issued an accounting standards update that provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company has adopted this guidance at the beginning of the first quarter of fiscal year 2014. The adoption of this standard does not have a material impact on the Company’s financial position, results of operations or related financial statement disclosures.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2014
Inventory	'
	2. Inventory
	The components of inventories are as follows (in thousands):
		June 30,			December 31,
		2014			2013
	Raw materials	$	242		$	147
	Work in process		497			446
	Finished goods		867			902
	Total		1,606			1,495
	Less: allowance for inventory obsolescence		(136	)		(126	)
	Inventory, net	$	1,470		$	1,369

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Property and Equipment	'
	3. Property and Equipment
	Property and equipment consists of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Machinery and equipment		1,347		$	1,170
	Computer equipment		250			246
	Office equipment		203			203
	Leasehold improvements		757			745
	Construction in progress		25			—
			2,582			2,364
	Less: accumulated depreciation and amortization		(1,735	)		(1,534	)
	Property and equipment, net	$	847		$	830
	Depreciation expenses for the three and six months ended June 30, 2014 were $101,000 and $202,000, respectively. During the same periods in the prior year, depreciation expenses were $100,000 and $201,000, respectively.

Patent_Licenses

Patent Licenses	6 Months Ended
	Jun. 30, 2014
Patent Licenses	'
	4. Patent Licenses
	On December 31, 2003, LCT entered into an Option to License Intellectual Property agreement with Advanced Cell Technology, Inc. (“ACT”) for patent rights and paid ACT $340,000 in option and license fees. On February 13, 2004, LCT and ACT amended the Option agreement and LCT paid ACT additional option fees of $22,500 for fees related to registering ACT’s patents in selected international countries.
	On May 14, 2004, LCT amended the licensing agreement with ACT for the exclusive worldwide patent rights for the following ACT technologies: UMass IP, ACT IP and Infigen IP. The additional license fees paid were $400,000.
	On February 7, 2013, the Company and ACT entered into Amended and Restated License Agreements (the “Amendment”) for the purpose of completely amending and restating the terms of the license agreements. Under the terms of the Amendment, the Company acquired exclusive world-wide rights to all human therapeutic uses and cosmetic uses from ATC and Infigen’s early work on parthenogenic-derived embryonic stem cells, as well as certain rights to patents covering Single Blastomere technology.
	Pursuant to the Amendment, all minimum R&D requirements and all milestone payments due to ACT under the Exclusive License Agreement have been eliminated. The Company will no longer pay any royalties under the ACT IP Agreement and Infigen IP Agreement. The obligation to pay royalties that ranged from 6%-12% under the UMass IP Agreement has been reduced to 0.25% of the net sales of products using technology covered by the UMass IP Agreement; and the obligation to pay a minimum annual license fee of $150,000 has been reduced to $75,000 annually, payable in two installments to ACT. As of June 30, 2014, the total amount capitalized related to the acquired ACT licenses was $747,000, and $2,273,000 related to the other patent acquisition costs.
	Patents and patent licenses were recorded at cost of $3,020,000 and $2,760,000 at June 30, 2014 and December 31, 2013, respectively. Amortization expense for the three months ended June 30, 2014 and 2013 was $16,000 and $15,000, respectively; and amortization expense for the six months ended June 30, 2014 and 2013 was $32,000 and $30,000, respectively. All amortization expense related to intangible assets is included in general and administrative expense. Accumulated amortization as of June 30, 2014 and December 31, 2013 was $542,000 and $510,000, respectively.
	At June 30, 2014, future amortization expense related to intangible assets subject to amortization is expected to be as follows (in thousands):
		Amount
	2014 (remaining six months)	$	31
	2015		62
	2016		62
	2017		62
	2018		62
	Thereafter		2,200
	Total	$	2,479

Advances

Advances	6 Months Ended
	Jun. 30, 2014
Advances	'
	5. Advances
	On June 18, 2008, the Company entered into an agreement with BioTime, Inc. (“Bio Time”), where Bio Time will pay an advance of $250,000 to LCT to produce, make, and distribute Joint Products. The $250,000 advance will be paid down with the first $250,000 of net revenues that otherwise would be allocated to LCT under the agreement. As of June 30, 2014 no revenues were realized from this agreement.
		June 30,		December 31,
		2014		2013
	BioTime, Inc. (in thousands)	$	250	$	250

Capital_Stock

Capital Stock	6 Months Ended
	Jun. 30, 2014
Capital Stock	'
	6. Capital Stock
	As of June 30, 2014, the Company is authorized to issue 600,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share.
	Preferred Stock Transactions
	Series B Preferred Stock
	On May 12, 2008, to obtain funding for working capital, the Company entered into a series of subscription agreements with five accredited investors for the sale of a total of 400,000 Series B Units, each Series B Unit consisting of one share of Series B Preferred Stock (“Series B Preferred”) and two Series B Warrants (“Series B Warrants”) to purchase common stock for each $1.00 invested.
	The total purchase price received by the Company was $400,000. The Series B Preferred is convertible into shares of common stock at the initial conversion ratio of two shares of common stock for each share of Series B Preferred converted (which was established based on an initial conversion price of $0.50 per share), and the Series B Warrants were exercisable at $0.50 per share until five years from the issuance of the Series B Warrants, which expired unexercised in May 2013. The Series B Preferred contain anti-dilution clauses whereby, if the Company issues equity securities or securities convertible into equity at a price below the conversion price of the Series B Preferred, such conversion price shall be adjusted downward to equal the price of the new securities. During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the conversion price of the Series B Preferred to $0.20. As a result of the 2013 S-1 July Registered Offering discussed below, the conversion price for the Series B Preferred was reduced to $0.15 and $0.1452 in the third and fourth quarters of 2013, respectively. During the second quarter of 2014, the 2014 Warrant Exchange Agreements discussed below triggered an adjustment in the current conversion price of the Series B Preferred to $0.0667 per share. The Series B Preferred has a priority (senior to the shares of common stock) on any sale or liquidation of the Company equal to the purchase price of the Series B Units, plus a liquidation premium of 6% per year. If the Company elects to declare a dividend in any year, it must first pay to the Series B Preferred holder a dividend equal to the amount of the dividend the Series B Preferred holder would receive if the Series B Preferred were converted just prior to the dividend declaration. Each share of Series B Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. As of June 30, 2014 and December 31, 2013, there were 300,000 shares of the Series B Preferred issued and outstanding.
	Series C Preferred Stock
	On August 20, 2008, 700,000 shares of Series C Preferred Stock (“Series C Preferred”) were sold, and 1,300,000 shares of Series C Preferred were sold on September 23, 2008 all at a price of $1.00 per Series C Preferred share. The Series C Preferred was convertible into shares of common stock at $0.25 per share. All the Series C Preferred was issued to X-Master Inc., which is a related party and affiliated with the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors, Dr. Andrey Semechkin, and Dr. Ruslan Semechkin, Chief Scientific Officer and a director.
	As of June 30, 2014 and December 31, 2013, there were 0 shares of the Series C Preferred issued and outstanding. On January 22, 2013, the holders of Series C Preferred converted all of the outstanding shares of Series C Preferred into common stock at $0.25 per share, or a total of 8,000,000 shares of common stock.
	On April 10, 2013, the Company filed a Certificate of Elimination for the Series C Preferred stock. The Certificate of Elimination amended the provisions of the Certificate of Incorporation of the Company to eliminate the powers, designations, preferences, privileges and other rights of the Series C Preferred stock.
	Series D Preferred Stock
	On December 30, 2008, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Agreement”) with accredited investors (the “Investors”) and sold 43 shares of Series D Preferred Stock (“Series D Preferred”) for total proceeds of $4,700,000 at a price of $100,000 per Series D Preferred share.
	10 shares of the Series D Preferred were issued to X-Master Inc., which is a related party and affiliated with the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors, Dr. Andrey Semechkin and Dr. Ruslan Semechkin, Chief Scientific Officer and a director; and 33 shares of the Series D Preferred were issued to Dr. Andrey Semechkin. As of June 30, 2014 and December 31, 2013, there were 43 shares of the Series D Preferred issued and outstanding.
	On December 4, 2012, the holders of all of the outstanding shares of Series D Preferred executed a Waiver of Anti-Dilution Rights (the “Anti-Dilution Waiver”) pursuant to which such holders waived all anti-dilution adjustment rights under the Certificate of Designation for the Series D Preferred in connection with the offering of securities pursuant to the registration statement originally filed with the SEC on October 18, 2012, including the shares issuable on exercise of all warrants registered thereunder. The Anti-Dilution Waiver applied to the financing transaction that closed on July 24, 2013. The Anti-Dilution Waiver does not apply to any future issuances of securities which would otherwise trigger anti-dilution adjustments under the Certificate of Designation for the Series D Preferred. During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the conversion price of the Series D Preferred to $0.20. During December 2013, the Company issued additional shares of common stock at $0.15 per share, triggering an adjustment in the conversion price of the Series D Preferred to $0.15 per share. During the second quarter of 2014, the 2014 Warrant Exchange Agreements discussed below triggered an adjustment in the current conversion price of the Series D Preferred to $0.0667 per share.
	Series G Preferred Stock
	On March 9, 2012, the Company entered into a Series G Preferred Stock Purchase Agreement (the “Series G Agreement”) with AR Partners, LLC (the “Purchaser”) to sell 5,000,000 shares of Series G Preferred Stock (“Series G Preferred”) at a price of $1.00 per Series G Preferred share, for a total purchase price of $5,000,000. The Purchaser is an affiliate of Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, and Dr. Ruslan Semechkin, Chief Scientific Officer and a director.
	The Series G Preferred was initially convertible into shares of common stock at $0.40 per share, resulting in an initial conversion ratio of 2.5 shares of common stock for every share of Series G Preferred. The conversion price may be adjusted for stock splits and other combinations, dividends and distributions, recapitalizations and reclassifications, exchanges or substitutions and is subject to a weighted-average adjustment in the event of the issuance of additional shares of common stock below the conversion price.
	The Series G Preferred shares have priority over the Series B Preferred and common stock on the proceeds from any sale or liquidation of the Company in an amount equal to the purchase price of the Series G Preferred, but such payment may be made only after payment in full of the liquidation preferences payable to holders of any shares of Series D Preferred then outstanding. Each share of Series G Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. As long as there are at least 1,000,000 shares of Series G Preferred outstanding, the holders of Series G Preferred have (i) the initial right to propose the nomination of two members of the Board, at least one of which such nominees shall be subject to the approval of the Company’s independent directors, for election by the stockholder’s at the Company’s next annual meeting of stockholders, or, elected by the full board of directors to fill a vacancy, as the case may be, and (ii) the right to approve any amendment to the certificate of incorporation, certificates of designation or bylaws, in manner adverse to the Series G Preferred, alter the percentage of board seats held by the Series G Preferred directors or increase the authorized number of shares of Series G Preferred. At least one of the two directors nominated by holders of the Series G Preferred shall be independent based on the NASDAQ listing requirements.
	The Company determined that the Series G Preferred have a contingent redemption feature allowing redemption by the holder under only some very limited circumstances (“deemed liquidation events”). As the event that may trigger the redemption of the convertible preferred stock is not solely within the Company’s control, the convertible preferred stock has been classified as mezzanine equity (outside of permanent equity) on the Company’s consolidated balance sheet. Additionally, legal costs related to the Series G Preferred financing in the amount of $59,000 were recorded in the mezzanine equity as well.
	As of June 30, 2014 and December 31, 2013, there were 5,000,000 shares of the Series G Preferred issued and outstanding.
	During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the conversion price and the conversion ratio of the Series G Preferred to $0.37 per share and 2.67 shares, respectively. As a result of the 2013 S-1 July Registered Offering during the third quarter of 2013, the conversion price and the conversion ratio for the Series G Preferred were adjusted to $0.30 per share and 3.28 shares, respectively. During December 2013, the Company issued additional shares of common stock at $0.15 per share, triggering an adjustment in the conversion price and the conversion ratio for the Series G Preferred to $0.3039 per share and 3.291 shares, respectively.
	During the first quarter of 2014, the Company issued additional shares of common stock, under the stock Purchase Agreement with Lincoln Park, at various prices ranging from $0.175 to $0.223 per share, triggering numerous adjustments in the conversion price and the conversion ratio of the Series G Preferred. During the second quarter of 2014, the Company issued additional shares of common stock, under the stock Purchase Agreement with Lincoln Park, at various prices ranging from $0.150 to $0.185 per share; and sold shares at $0.15 and $0.10 per share to Dr. Andrey Semechkin and Dr. Ruslan Semechkin, the Company’s Co-Chairman and Chief Executive Officer, and Chief Scientific Officer and a director, respectively, triggering numerous adjustments in the conversion price and the conversion ratio of the Series G Preferred. Also during the second quarter of 2014, common shares were issued at $0.0667 per share as part of the 2014 Warrant Exchange Agreements discussed below. As of June 30, 2014, the adjusted conversion price and the conversion ratio for the Series G Preferred were $0.2545 per share and 3.9289 shares, respectively.
	Common Stock Transactions
	2013 Securities Purchase Agreements for Common Stock
	On January 22, 2013, to obtain funding for working capital purposes, the Company entered into a securities purchase agreement with Dr. Andrey Semechkin and Dr. Simon Craw to sell a total of 10,125,000 shares of common stock at a price of $0.20 per share, for a total purchase price of $2,025,000. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer. Dr. Simon Craw is the Company’s Executive Vice President Business Development. The sale of the shares of common stock was completed on January 22, 2013. In connection with the sale of these shares the Company issued to each purchaser a warrant, exercisable for a period of 5 years, to purchase a number of shares of common stock equal to 50% of the shares purchased by that purchaser, for a total of 5,062,500 shares subject to the warrants at an exercise price of $0.20 per share.
	On March 12, 2013, to obtain funding for working capital purposes, the Company entered into a securities purchase agreement with certain investors, including Dr. Andrey Semechkin, to sell a total of 5,000,000 shares of common stock at a price of $0.20 per share, for a total purchase price of $1,000,000. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer and purchased $100,000 worth of common stock. Each of the other investors has had a long-standing relationship with the Company and has closely followed the Company. The sale of the shares of common stock was completed on March 12, 2013. In connection with the sale of these shares the Company issued to each investor a warrant, exercisable for a period of five years, to purchase a number of shares of common stock equal to 50% of the shares purchased by that investor, for a total of 2,500,000 shares subject to the warrants at an exercise price of $0.20 per share.
	2013 S-1 July Registered Offering
	On July 19, 2013, to obtain funding for working capital purposes, the Company entered into subscription agreements with certain investors (the “Investors”) relating to the sale by the Company of (i) 20,000,000 Units (each a “Unit”, and collectively, the “Units”), with each Unit consisting of (x) one share of common stock, par value $0.001 per share, and (y) one Series A Warrant to purchase one share of the Company’s common stock at an exercise price of $0.15 per share and (ii) 20,000,000 Series B Warrants, each to purchase one Unit, for aggregate gross proceeds of $3,000,000, before placement agent fees and other estimated offering expenses and fees (the “Offering”). The Units were not issued or certificated. The Investors received only shares of common stock, Series A Warrants and Series B Warrants. The common stock, the Series A Warrants and the Series B Warrants were and may be transferred separately immediately after their issuance. Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, purchased 5,998,999 Units and 5,998,999 Series B Warrants in the Offering; and Ruslan Semechkin, the Company’s Chief Scientific Officer, purchased 667,667 Units and 667,667 Series B Warrants in the Offering for an aggregate price of $1,000,000.
	On July 19, 2013, the Company also entered into a placement agent agreement (the “Placement Agent Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act on a reasonable best efforts basis for the Offering. The Company paid the Placement Agent a cash fee equal to 5% of the gross proceeds from the Offering and reimbursed the Placement Agent for its reasonable out-of-pocket expenses of $75,000. The Company also issued 666,666 Placement Agent Warrants to purchase Units equal to 5% of the aggregate number of Units issued in the Offering (other than the Units issued to Andrey Semechkin and Ruslan Semechkin). The Placement Agent Warrants have substantially the same terms as the Series B Warrants, except that the Placement Agent Warrants (i) have an exercise price of $0.15 per Unit, subject to adjustments similar to those applicable to the Series A Warrants, (ii) have a term of five years, (iii) provide for a cashless exercise, and (iv) otherwise comply with the requirements of the Financial Institutions Regulatory Authority, Inc. (FINRA). The Company also agreed to pay the Placement Agent a cash solicitation fee equal to 5% of the gross proceeds received by the Company upon the exercise of the Series B Warrants under certain circumstances. See 2014 Warrant Exchange Agreements below for the detailed discussion of common stock issued in the second quarter of 2014 in exchange for the cancellation of the warrants.
	The Series A Warrants were immediately exercisable at an exercise price of $0.15 per share and will expire on the fifth anniversary of the initial date of issuance. Upon full exercise of the Series B Warrants, the Company could issue additional Series A Warrants to purchase up to an aggregate of 20,000,000 shares of the Company’s common stock. All Series A Warrants have the same expiration date. See 2014 Warrant Exchange Agreements below for the detailed discussion of common stock issued in the second quarter of 2014 in exchange for the cancellation of the warrants. See Note 9, Stock Options and Warrants, Warrants Issued with Common Stock for detailed discussion of the anti-dilution provisions of the Series A Warrants.
	The Series B Warrants were immediately exercisable at an initial exercise price of $0.15, subject to adjustment and expired on October 24, 2013.
	The net proceeds to the Company from the Offering, after deducting placement agent fees and cash offering expenses borne by the Company, and excluding any proceeds, from the exercise of the warrants issued in the offering, was approximately $2,377,000. The Offering closed on July 24, 2013.
	During the year ended December 31, 2013, the Company received net proceeds of $2,356,000 upon the exercise of 16,754,822 of the Series B Warrants issued in July 2013 for 16,754,822 additional Units, but prior to expiration of the Series B Warrants on October 24, 2013. The total additional Units consisted of 16,754,822 shares of common stock and 16,754,822 Series A Warrants. Of the 16,754,822 Series B Warrants exercised during the year ended December 31, 2013, there were 12,304,822 subject to an adjusted exercise price of $0.1452 per Unit for net proceeds of approximately $1,722,000. The remaining 4,450,000 were exercised prior to the adjustment date at $0.15 per Unit for net proceeds of approximately $634,000. See Note 9, Stock Options and Warrants, Warrants Issued with Common Stock for detailed discussion of the price adjustment provisions of the Series B Warrants.
	Of the Series B Warrants exercised, Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, exercised 2,754,821 Series B Warrants; and Ruslan Semechkin, the Company’s Chief Scientific Officer, exercised 667,667 Series B Warrants for an aggregate price of $497,000.
	In addition, during the year ended December 31, 2013, the Company received net proceeds of $30,000 upon the exercise of 200,000 of the Series A Warrants issued in July 2013 for 200,000 shares of common stock at an exercise price of $0.15 per share.
	On October 24, 2013, the remaining 3,245,178 Series B Warrants expired unexercised. At June 30, 2014, there were no Series A and Placement Agent warrants outstanding. See 2014 Warrant Exchange Agreements below for the detailed discussion of common stock issued in the second quarter of 2014 in exchange for the cancellation of the warrants. At December 31, 2013, total Series A and Placement Agent warrants outstanding were 36,554,822 and 666,666, respectively, which the Company had reserved 37,888,154 shares of common stock for future issuance.
	2014 Securities Purchase Agreements for Common Stock
	On May 29, 2014, to obtain funding for working capital purposes, the Company entered into a securities purchase agreement with Dr. Andrey Semechkin and Dr. Ruslan Semechkin to sell a total of 3,333,333 shares of common stock at a price of $0.15 per share, for a total purchase price of $500,000. On June 26, 2014, to obtain funding for working capital purposes, the Company entered into a securities purchase agreement with Dr. Andrey Semechkin and Dr. Ruslan Semechkin to sell a total of 5,500,000 shares of common stock at a price of $0.10 per share, for a total purchase price of $550,000. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer. Dr. Ruslan Semechkin is the Company’s Chief Scientific Officer and director.
	2014 Warrant Exchange Agreements
	On June 11, 2014, the Company entered into a series of warrant exchange agreements (the “Warrant Exchange Agreements”) with the holders of its Series A Warrants and Placement Agent Warrants that were issued by the Company pursuant to the 2013 S-1 July Registered Offering. Under the Warrant Exchange Agreements, the Company agreed to issue a total of 44,665,783 shares of common stock (the “Exchange Shares”) to the warrant holders in exchange for the cancellation of the Series A Warrants to purchase 36,554,822 shares of common stock and the Placement Agent Warrants to purchase 666,666 shares of common stock and Series A Warrants. Dr. Andrey Semechkin and Dr. Ruslan Semechkin, the Company’s Co-Chairman and Chief Executive Officer and Chief Scientific Officer and director, respectively, participated on the same terms as the other warrant holders, agreeing to exchange Series A Warrants to purchase 10,088,154 shares of common stock for 12,105,784 shares of common stock. The closing of the transaction occurred on June 16, 2014 with the issuance of the Exchange Shares. Upon settlement of the exchange transaction, there were no remaining Series A Warrants or Placement Agent Warrants outstanding. See Note 9, Stock Options and Warrants, 2014 Warrants Exchange Agreements- for detailed discussion of the accounting treatment of the Warrant Exchange transaction.
	As part of the Warrant Exchange Agreement, the Company agreed that through September 14, 2014 it would not offer, sell, pledge, contract to sell or otherwise dispose of any equity securities or securities convertible, exercisable or exchangeable into equity securities of the Company, except for the issuance of equity awards pursuant to the Company’s employee benefit plans and employee incentive plans, the issuance of common stock pursuant to the valid exercise of options or warrants or upon exercise of conversion rights with respect to convertible securities outstanding on the date of the Warrant Exchange, and the issuance and sale of equity securities in private placements to directors or officers of the Company.
	2013 Lincoln Park Capital Fund, LLC Stock Purchase Agreement
	On December 10, 2013, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase up to an aggregate of $10,250,000 of common stock (subject to certain limitations) from time to time through January 2017. Of the aggregate $10,250,000 of common stock that may be sold to Lincoln Park, on December 11, 2013, the Company sold 1,666,666 shares of common stock to Lincoln Park for an aggregate purchase price of $250,000 pursuant to the Purchase Agreement, which is referred to as the Initial Purchase. Upon execution of the Purchase Agreement, the Company paid to Lincoln Park $155,000, as a cash fee, for their commitment to purchase additional shares of common stock under the Purchase Agreement.
	Also on December 10, 2013, the Company entered into a Registration Rights Agreement with Lincoln Park, pursuant to which the Company filed with the SEC an S-1 Registration Statement to register for resale under the Securities Act of 1933, as amended, or the Securities Act, the shares that have been or may be issued to Lincoln Park under the Purchase Agreement. The S-1 Registration Statement filed with the Securities and Exchange Commission in December 2013 and amended in January 2014 was declared effective on January 13, 2014.
	During the three and six months ended June 30, 2014, the Company sold 3,000,000 and 8,200,000 shares, respectively, to Lincoln Park raising approximately $484,000 and $1,588,000, respectively, for working capital purposes. From commencement through to June 30, 2014, the Company has sold a total of 9,866,666 shares of common stock to Lincoln Park for an aggregate of $1,838,000 under the Agreement. As of June 30, 2014, there remained 10,133,334 shares available for sale up to a total of $8,412,000 under the Purchase Agreement with Lincoln Park.
	The Company may, from time to time and in its sole discretion, direct Lincoln Park to purchase shares of common stock in amounts up to 200,000 shares on any single business day so long as at least one business day has passed since the most recent purchase, which amounts may be increased to up to 300,000 shares and up to 400,000 shares, provided the closing price of the common stock exceeds a certain threshold, with a maximum limit of up to $500,000 per purchase, plus an additional “accelerated amount” under certain circumstances. There are no trading volume requirements or restrictions under the Purchase Agreement, and the Company will control the timing and amount of any sales of common stock to Lincoln Park. The purchase price of the shares that may be sold to Lincoln Park under the Purchase Agreement will be based on the market price of the common stock immediately preceding the time of sale as computed under the Purchase Agreement without any fixed discount; provided that in no event will such shares be sold to Lincoln Park when the closing sale price is less than $0.05 per share, subject to adjustment as provided in the Purchase Agreement.
	The purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the business days used to compute such price. The Company may at any time in its sole discretion terminate the Purchase Agreement without fee, penalty or cost upon one business day notice. Lincoln Park may not assign or transfer its rights and obligations under the Purchase Agreement.
	Aspire Common Stock Purchase Agreement
	On December 9, 2010, Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”), which provided that, subject to certain conditions and limitations, Aspire Capital was committed to purchase up to an aggregate of $25,000,000 of common stock over the term of the Purchase Agreement. The Purchase Agreement expired in December 2013.
	On any day on which the principal market for shares of the Company’s common stock is open for trading, over the three-year term of the Purchase Agreement, the Company had the right, in its sole discretion, to provide Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase the number of shares of common stock specified in the Purchase Notice. The number of shares the Company could designate in the Purchase Notice varied based on the closing price of the common stock on the date of the Purchase Notice. The purchase price per share for each Purchase Notice was the lower of (i) the lowest sale price for the common stock on the date of sale or (ii) the arithmetic average of the three lowest closing sale prices for the common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date of those securities.
	During the three months and six months ended June 30, 2013, the Company issued 0 and 1,200,000 shares of common stock, respectively, to Aspire Capital, raising $0 and $264,000, respectively, which was used to fund its research and operational activities.
	Reserved Shares
	At June 30, 2014, the Company had shares of common stock reserved for future issuance as follows:
	Options outstanding	27,318,410
	Options available for future grant	8,396,333
	Convertible preferred stock	88,634,236
	Warrants	7,762,500
		132,111,479

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions	'
	7. Related Party Transactions
	Other than with respect to the purchases of Series C Preferred, Series D Preferred, Series G Preferred, and common stock transactions discussed above, the Company’s related party transactions were for a facility lease.
	During the first quarter of 2011, the Company executed an operating lease for its corporate offices with S Real Estate Holdings LLC. S Real Estate Holdings LLC is owned by Dr. Ruslan Semechkin, the Company’s Chief Scientific Officer and a director and was previously owned by Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors. The lease agreement was negotiated at arm’s length and was reviewed by the Company’s outside legal counsel. The terms of the lease were reviewed by a committee of independent directors, and the Company believes that, in total, those terms are at least as favorable to the Company as could be obtained for comparable facilities from an unaffiliated party. For the three months ended June 30, 2014 and 2013, the Company recorded $41,000 and $45,000, respectively, in rent expense that was related to the facility lease arrangement with related parties. Additionally, during the six months ended June 30, 2014 and 2013, the Company recorded $81,000 and $79,000, respectively, related to the same arrangement with the related party.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes	'
	8. Income Taxes
	The Company estimated Federal and state tax losses for the current year and recorded a full valuation allowance against all net deferred tax assets. As such, no income tax provision has been recorded for the current period. The Company may be subject to IRC Code Sections 382 and 383, which could limit the amount of the net operating loss and tax credit carryovers that can be used in future years. The Company has not completed a study to assess whether an ownership change has occurred, as defined by IRC Code Sections 382 and 383, or whether there have been ownership changes since the Company’s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. The Company estimates that if such a change did occur, the federal and state net operating loss carryforwards and research and development credit carryforwards that can be utilized in the future will be significantly limited. There can be no assurances that the Company will ever be able to realize the benefit of some or all of the federal and state loss carryforwards or the credit carryforwards, either due to ongoing operating losses or due to ownership changes, which limit the usefulness of the carryforwards.

Stock_Options_and_Warrants

Stock Options and Warrants	6 Months Ended
	Jun. 30, 2014
Stock Options and Warrants	'
	9. Stock Options and Warrants
	Stock Options
	The Company adopted the 2006 Equity Participation Plan (the “2006 Plan”), which provides for the grant of stock options, restricted stock and other equity based awards. Awards for up to 15,000,000 shares may be granted to employees, directors and consultants under this Plan. The options granted under the 2006 Plan may be either qualified or non-qualified options. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant.
	In April 2010, the Company adopted the 2010 Equity Participation Plan (the “2010 Plan”), which provides for the grant of stock options, restricted stock and other equity based awards. Awards for up to 18,000,000 shares may be granted to employees, directors and consultants under the 2010 Plan. The options granted under the 2010 Plan may be either qualified or non-qualified options. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant.
	In November and December of 2009, the Company issued non-qualified stock options to purchase 10,257,593 shares of common stock outside the 2006 and 2010 option plans to certain employees and consultants. These options vest over 50 months and expire no later than 10 years from the date of grant.
	Total stock-based compensation expense for the three and six months ended June 30, 2014 and 2013 was comprised of the following (in thousands):
		Three Months Ended			Three Months Ended			Six Months Ended				Six Months Ended
		June 30,			June 30,			June 30,				June 30,
		2014			2013			2014				2013
	Cost of sales	$	15		$	—		$	30			$	—
	Research and development		73			93			143				177
	Selling and marketing		12			10			23				19
	General and administrative		274			337			525				653
		$	374		$	440		$	721			$	849
	Unrecognized compensation expense related to stock options as of June 30, 2014 was $1,562,000, which is expected to be recognized over a weighted average period of approximately 1.78 years.
	In accordance with applicable authoritative guidance, the Company is required to establish assumptions and estimates of the weighted-average fair value of stock options granted, as well as use a valuation model to calculate the fair value of stock-based awards. The Company uses the Black-Scholes option-pricing model to determine the fair-value of stock-based awards. All options are amortized over the requisite service periods. Stock-based compensation for stock options granted to non-employees has been determined using the Black-Scholes option pricing model. These options are revalued at each reporting period until fully vested, with any change in fair value recognized in the consolidated statements of operations.
	The fair value of options granted is estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended			Three Months Ended			Six Months Ended				Six Months Ended
		June 30,			June 30,			June 30,				June 30,
		2014			2013			2014				2013
	Significant assumptions (weighted average):
	Risk-free interest rate at grant date		1.91	%		0.95	%		1.91	%			0.95	%
	Expected stock price volatility		99.72	%		118.34	%		99.72	%			118.34	%
	Expected dividend payout		0	%		0	%		0	%			0	%
	Expected option life based on management's estimate	6.1 yrs			6.1 yrs			6.1 yrs				6.1 yrs
	Transactions involving stock options issued to employees, directors and consultants under the 2006 Plan, the 2010 Plan and outside the plans are summarized below. Options issued have a maximum life of 10 years. The following tables summarize the changes in options outstanding and the related exercise prices for the Company’s common stock options issued:
		Number of						Weighted
		Shares Issued			Weighted			Average		Aggregate
		Under			Average Exercise			Remaining		Intrinsic
		2006 Plan and			Price Per			Contractual		Value
		2010 Plan			Share			Term		(in thousands)
	Outstanding at December 31, 2012		15,122,900		$	1.18
	Granted		1,491,500		$	0.26
	Exercised		—		$	—
	Canceled or expired		(586,000	)	$	0.61
	Outstanding at December 31, 2013		16,028,400		$	1.12
	Granted		4,104,000		$	0.16
	Exercised		—		$	—
	Canceled or expired		(423,283	)	$	0.72
	Outstanding at June 30, 2014		19,709,117		$	0.93		6.72 years		$	—
	Vested and expected to vest at June 30, 2014		18,704,421		$	0.97		6.57 years		$	—
	Exercisable at June 30, 2014		12,626,784		$	1.2		5.48 years		$	—
								Weighted
		Number of			Weighted			Average		Aggregate
		Shares Issued			Average Exercise			Remaining		Intrinsic
		Outside			Price Per			Contractual		Value
		the Plan			Share			Term		(in thousands)
	Outstanding at December 31, 2012		8,254,232		$	0.65
	Granted		—		$	—
	Exercised		—		$	—
	Canceled or expired		(644,939	)	$	1
	Outstanding at December 31, 2013		7,609,293		$	0.62
	Granted		—		$	—
	Exercised		—		$	—
	Canceled or expired		—		$	—
	Outstanding, vested and exercisable at June 30, 2014		7,609,293		$	0.62		5.36 years		$	—
	Restricted Stock Awards
	Restricted stock awards are grants that entitle the holder to acquire shares of common stock at zero or a fixed price, which is typically nominal. The Company accounts for the restricted stock awards as issued and outstanding common stock, even though the shares covered by a restricted stock award cannot be sold, pledged, or otherwise disposed of until the award vests and any unvested shares may be reacquired by the Company for the original purchase price following the awardee’s termination of service. Annual grants of restricted stock awards are made to the non-employee members of the board of directors on the date of the annual meeting of stockholders and typically vest in full at the next annual meeting of stockholders following the grant date. Beginning in 2013, additional annual grants of restricted stock awards were made to the non-employee members of the board of directors as partial compensation for their services. These awards vest quarterly at the end of each quarter. In addition, the Company has made restricted stock awards to non-employee consultants for their services, which generally vest in one year or less.
	The following table summarizes the changes in restricted stock award activity and the related weighted average exercise prices for the Company’s awards issued:
		Restricted
		Stock Issued
		from the			Weighted
		2006 Plan and			Average Grant Date
	2010 Plan			Fair Value
Unvested at December 31, 2012		335,000		$	0.32
Granted		961,000		$	0.24
Vested		(1,029,750	)	$	0.27
Forfeited		(121,250	)	$	0.25
Unvested at December 31, 2013		145,000		$	0.23
Granted		716,500		$	0.21
Vested		(388,750	)	$	0.23
Forfeited		—		$	—
Unvested at June 30, 2014		472,750		$	0.2
The fair value of the restricted stock awards is based on the market value of the common stock on the date of grant. The total grant-date fair value of restricted stock awards vested during the six months ended June 30, 2014 and 2013 was approximately $91,000 and $188,000, respectively. The Company recognized approximately $46,000 and $69,000 of stock-based compensation expense related to the restricted stock awards for the three months ended June 30, 2014 and 2013, respectively. Additionally, during the six months ended June 30, 2014 and 2013, the Company recognized approximately $85,000 and $137,000 of stock-based compensation expense related to the restricted stock awards, respectively. As of June 30, 2014, total unrecognized compensation costs related to unvested awards was approximately $84,000, which is expected to be recognized over a weighted-average period of approximately 0.57 years.
Warrants
Warrants Issued with Preferred Stock
During 2008, in connection with the Company’s fund raising efforts, two warrants to purchase shares of common stock were issued with the purchase of one share of Series A Preferred Stock, where an additional 2,000,000 common stock warrants were outstanding and two warrants to purchase shares of common stock were issued with the purchase of one share of Series B Preferred Stock, where an additional 1,100,000 common stock warrants were outstanding. During the second quarter of 2010, the holders of the warrants issued to the purchasers of the Series A Preferred Stock and Series B Preferred Stock signed a waiver to give up their rights to the anti-dilution provisions related to the warrants and the exercise price was fixed at $0.25.
As of December 31, 2013, there were no outstanding warrants related to the Series A Preferred Stock and Series B Preferred Stock. Warrants related to the Series A Preferred Stock expired in January 2013, and warrants related to the Series B Preferred Stock expired in July 2013.
Warrants Issued with Common Stock
2013 Securities Purchase Agreements for Common Stock
In conjunction with the Company’s sale of 10,125,000 shares of common stock on January 22, 2013, the Company issued warrants convertible into 5,062,500 shares of common stock at an exercise price of $0.20 per share. The warrants have a five-year term. These warrants are held by Dr. Andrey Semechkin and Dr. Simon Craw, the Company’s Co-Chairman and Chief Executive Officer and the Company’s Executive Vice President Business Development, respectively.
On March 12, 2013 the Company issued warrants convertible into 2,500,000 shares of common stock in conjunction with the sale of 5,000,000 shares of common stock. These warrants have a five-year term and an exercise price of $0.20 per share. Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer is the holder of 250,000 of these warrants.
2013 S-1 July Registered Offering
On July 24, 2013 the Company sold 20,000,000 Units, with each Unit consisting of one share of common stock and one Series A Warrant. The Series A Warrants were convertible into 20,000,000 shares of common stock at an exercise price of $0.15 per share. The warrants have a five year term and were immediately exercisable. In addition, the Company issued 20,000,000 Series B Warrants each to purchase one Unit. The Series B Warrants were immediately exercisable at an initial exercise price of $0.15 per Unit, subject to adjustment and expired on October 24, 2013. The Units issuable upon exercise of the Series B Warrants consisted of 20,000,000 shares of common stock and 20,000,000 Series A Warrants, which were convertible into an additional 20,000,000 shares of common stock at an exercise price of $0.15 per share. All Series A Warrants had an expiration date of the fifth anniversary of the transaction close, July 24, 2018, regardless of the date the Series A Warrants were issued. See the 2014 Warrant Exchange Agreements - discussed below.
On July 19, 2013, the Company also entered into a placement agent agreement (the “Placement Agent Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act on a reasonable best efforts basis for the Offering. The Company paid the Placement Agent a cash fee equal to 5% of the gross proceeds from the Offering and reimbursed the Placement Agent for its reasonable out-of-pocket expenses of $75,000. The Company also issued 666,666 Placement Agent Warrants to purchase Units equal to 5% of the aggregate number of Units issued in the Offering (other than the Units issued to Andrey Semechkin and Ruslan Semechkin). The Placement Agent Warrants had substantially the same terms as the Series B Warrants, except that the Placement Agent Warrants (i) had an exercise price of $0.15 per Unit, subject to adjustments similar to those applicable to the Series A Warrants, (ii) had a term of five years, (iii) provided for a cashless exercise, and (iv) otherwise comply with the requirements of the Financial Institutions Regulatory Authority, Inc. (FINRA). The Company also agreed to pay the Placement Agent a cash solicitation fee equal to 5% of the gross proceeds received by the Company upon the exercise of the Series B Warrants under certain circumstances. See the 2014 Warrant Exchange Agreements - discussed below.
The Series B Warrants were immediately exercisable at an initial exercise price of $0.15, subject to adjustment. Beginning at the close of trading on the 60th trading day following the date of issuance, and effective beginning on the fifth trading day immediately preceding such 60th trading day, the Series B Warrants were exercisable at a per unit exercise price equal to the lower of (i) the then-effective exercise price per unit and (ii) 80% of the closing bid price of the Company’s common stock on such 60th trading day. If prior to the close of trading on the 60th trading day after the date of issuance (and on any of the five trading days immediately preceding such day), a holder of the Series B Warrants had delivered one or more exercise notices to the Company and paid all or any part of the exercise price with respect thereto, then on the first trading day immediately following such 60th trading day the Company was obligated to deliver to such holder an amount in cash equal to the positive difference (if any) between (x) the exercise price actually paid by such holder and (y) the product of (I) the aggregate number of units elected to be purchased in such exercise notices, multiplied by (II) 80% of the closing bid price of the Company’s common stock on such 60th trading day. The Series B Warrants expired at the close of business on the 65th trading day following the date of issuance, October 24, 2013. The Series B Warrants were issued separately from the common stock and the Series A Warrants included in the Units, and were transferable separately, immediately thereafter. Series B Warrants were issued in certificated form only. Investors in the Offering received one Series B Warrant for each Unit purchased by them in the Offering. No additional consideration was paid by holders of the Series B Warrants.
The exercise price and number of shares of common stock issuable upon exercise of the Series A Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction, as described in the Series A Warrants. The Series A Warrants also contained full ratchet anti-dilution protection upon the issuance of any common stock, securities convertible into common stock, or certain other issuances at a price below the then existing exercise price of the Series A Warrants, with certain exceptions. The exercise price and number of Units issuable on exercise of the Series B Warrants were subject to adjustment in the event of any stock split, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction, as described in the Series B Warrants.
The Series A Warrants were exercisable on a “cashless” basis in certain circumstances. In addition, in the event of a fundamental transaction that is (i) an all cash or substantially all cash transaction, (ii) a “Rule 13e 3 transaction” as defined in Rule 13e-3 under the Securities Exchange Act of 1934, as amended, or (iii) with certain limited exceptions, a fundamental transaction involving a person or entity not traded on The New York Stock Exchange, Inc., The NYSE MKT, The NASDAQ Global Select Market, The NASDAQ Global Market or The NASDAQ Capital Market, then the Company or any successor entity would pay at the holder’s option, exercisable at any time concurrently with or within 45 days after the consummation of the fundamental transaction, an amount of cash equal to the value of the Series A Warrant as determined in accordance with the Black Scholes option pricing model.
The Company has accounted for the warrants in accordance with current accounting guidance, which defines how freestanding contracts that are indexed to and potentially settled in a Company’s own stock should be measured and classified. The authoritative accounting guidance prescribes that only warrants issued under contracts that cannot be net-cash settled and are both indexed to and settled in the Company’s common stock can be classified as equity. As the Series A Warrant, Series B Warrant, and Placement Agent Warrant agreements did not meet the specific conditions for equity classification, the Company was required to classify the fair value of the warrants issued as a liability, with subsequent changes in fair value to be recorded as income (loss) in the statement of operations upon revaluation of the fair value of warrant liability at each reporting period. Valuation of the Warrants was estimated at each quarter and as of the year ended December 31, 2013 using the Monte-Carlo simulation model. The following assumptions were used as inputs to the model at December 31, 2013: stock price of $0.21 and warrant exercise price of $0.15 as of the valuation date; the Company’s historical stock price volatility of 84.3%; risk free interest rate on U.S. treasury notes of 1.55%; warrant expiration of 4.56 years; and a zero dividend rate for the Series A Warrants and the Placement Agent Warrants; simulated as a daily interval and anti-dilution impact if the Company had to raise capital below $0.15 per share.
The fair value of the warrant liability at the issuance date exceeded the gross proceeds received for the common shares, Series A Warrants and the Series B Warrants by $1,390,000. The Series A Warrants, Series B Warrants, and Placement Agent Warrants had fair values of $1,725,000, $2,645,000 and $115,000 at issuance, respectively. The classification and valuation of the warrants resulted in total warrant liabilities of $4,485,000 and $4,925,000 as of the issuance date of July 24, 2013 and the revaluation date of December 31, 2013, respectively. During the three and six months ended June 30, 2014, the Company recorded a net change in fair value of warrant liability gain of $1,271,000 and $1,894,000, respectively, in the unaudited condensed consolidated statements of operations prior to the 2014 Warrant Exchange Transaction in the second quarter of 2014 and for the quarterly revaluation at March 31, 2014. See the 2014 Warrant Exchange Agreements - discussed below.
Series A and B Warrant Exercises - There were no warrant exercises during the three and six months ended June 30, 2014. During the year ended December 31, 2013, the Company received net proceeds of $2,356,000 upon the exercise of 16,754,822 of the Series B Warrants issued in July 2013 for 16,754,822 additional Units, but prior to the expiration of the Series B Warrants on October 24, 3013. The total additional Units consisted of 16,754,822 shares of common stock and 16,754,822 Series A Warrants. Of the Series B Warrants exercised, Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, exercised 2,754,821 Series B Warrants; and Ruslan Semechkin, the Company’s Chief Scientific Officer, exercised 667,667 Series B Warrants for an aggregate price of $497,000.
In addition, during the year ended December 31, 2013, the Company received net proceeds of $30,000 upon the exercise of 200,000 of the Series A Warrants issued in July 2013 for 200,000 shares of common stock at an exercise price of $0.15 per share.
Series B Price Adjustment - The Series B Warrants were subject to an exercise price adjustment on the 60th trading day following issuance in July 2013. On October 17, 2013, the adjustment date, the adjusted exercise price was calculated at a 20% discount to the closing bid price on the adjustment date. The closing bid price on the adjustment date was $0.1815 per share, which resulted in an adjusted exercise price of $0.1452 per Unit. This adjusted exercise price was retroactively applied to all exercises from the period of October 10th through to the expiration date of October 24th. Of the 16,754,822 Series B Warrants exercised during the year ended December 31, 2013, there were 12,304,822 subject to the adjusted exercise price of $0.1452 per Unit for net proceeds of approximately $1,722,000. The remaining 4,450,000 were exercised prior to the adjustment date at $0.15 per Unit for net proceeds of approximately $634,000.
Expiration of Series B Warrants - On October 24, 2013, the remaining 3,245,178 Series B Warrants expired unexercised.
2014 Warrant Exchange Agreements – On June 11, 2014, the Company entered into a series of warrant exchange agreements (the “Warrant Exchange Agreements”) with the holders of its Series A Warrants and Placement Agent Warrants that were issued by the Company pursuant to the 2013 S-1 July Registered Offering. Under the Warrant Exchange Agreements, the Company agreed to issue a total of 44,665,783 shares of common stock (the “Exchange Shares”) to the warrant holders in exchange for the cancellation of the Series A Warrants to purchase 36,554,822 shares of common stock and the Placement Agent Warrants to purchase 666,666 shares of common stock and Series A Warrants. Dr. Andrey Semechkin and Dr. Ruslan Semechkin, the Company’s Co-Chairman and Chief Executive Officer and Chief Scientific Officer and director, respectively, participated on the same terms as the other warrant holders, agreeing to exchange Series A Warrants to purchase 10,088,154 shares of common stock for 12,105,784 shares of common stock. The closing of the transaction occurred on June 16, 2014 with the issuance of the Exchange Shares.
Immediately prior to the Warrant Exchange transaction, the Company recorded a net change in fair value of warrant liability gain of $1,271,000. As a result of the Warrant Exchange, the Company recognized a $3,445,000 loss for the warrant exchange inducement expense. In addition, the Company recorded a reclassification of $3,031,000 to additional paid in capital from warrant liability for a total increase to additional paid in capital of $6,428,000, which represents the fair value of the stock issued in the Warrant Exchange.
As part of the Warrant Exchange Agreement, the Company agreed that through September 14, 2014 it would not offer, sell, pledge, contract to sell or otherwise dispose of any equity securities or securities convertible, exercisable or exchangeable into equity securities of the Company, except for the issuance of equity awards pursuant to the Company’s employee benefit plans and employee incentive plans, the issuance of common stock pursuant to the valid exercise of options or warrants or upon exercise of conversion rights with respect to convertible securities outstanding on the date of the Warrant Exchange, and the issuance and sale of equity securities in private placements to directors or officers of the Company.
As of June 30, 2014 and December 31, 2013, there were 0 and 36,554,822 Series A Warrants and 0 and 666,666 Placement Agent Warrants outstanding, respectively, which the Company had reserved 0 and 37,888,154 shares of common stock for future issuance, respectively.
Warrants Issued with Other Financings
During 2007 and 2008, the Company entered into various agreements to borrow working capital and as part of these agreements, the Company issued warrants to the holders to purchase common stock. The Company issued 1,400,000 warrants to YKA Partners, an affiliated company of its former Co-Chairman of the Board with an exercise price of $0.25 per share, all of which expired unexercised in August 2013.
Warrants Issued in Connection with SkinCare Marketing Agreement
In September 2011, the Company signed a Marketing Agreement (“agreement”) with an effective date of June 30, 2011, with a third party marketing organization. According to the terms of the agreement as described in Note 10 below, Commitments and Contingencies, under Marketing Arrangement and Agreement, the third party marketing organization would provide assistance to LSC to sell its skin care products through various specific proprietary mailings. The agreement provides for two tranches of common stock warrants issued by the Company for the benefit of the third party marketing organization for 100,000 shares each, with strike prices of $1.50 and $2.00, respectively, vesting over four quarters, and a warrant term of five years. As of June 30, 2014 and December 31, 2013, there were 200,000 warrants outstanding. These warrants expire in September 2016.
Share data related to warrant transactions through June 30, 2014 were as follows:
	Preferred Stock						Common Stock							Units			Common Stock												Price per Warrant
																															Weighted
														Placement			YKA			Skin Care		Jan-13		Mar-13		Total					Average
	Series A			Series B			Series A				Series B			Agent			Loan			Marketing		Financing		Financing		Warrants			Range		Exercise Price
Outstanding,		1,600,000			300,000			—				—			—			1,400,000			200,000		—		—		3,500,000		$	0.25-2.00	$	0.336
December 31, 2012
2013
Issued								36,754,822				20,000,000			666,666								5,062,500		2,500,000		64,983,988		$	0.15-0.200	$	0.156
Exercised								(200,000	)			(16,754,822	)														(16,954,822	)	$	0.145-0.15	$	0.147
Forfeited/Cancelled		(1,600,000	)		(300,000	)						(3,245,178	)					(1,400,000	)								(6,545,178	)	$	0.15-0.250	$	0.198
Outstanding,		—			—			36,554,822				—			666,666			—			200,000		5,062,500		2,500,000		44,983,988		$	0.145-2.00	$	0.166
December 31, 2013
2014
Issued																											—
Exchanged								(36,554,822	)						(666,666	)											(37,221,488	)	$	0.15	$	0.15
Exercised																											—
Forfeited/Cancelled																											—
Outstanding,		—			—			—				—			—			—			200,000		5,062,500		2,500,000		7,762,500		$	0.145-2.00	$	0.24
June 30, 2014

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
	10. Commitments and Contingencies
	Leases
	The Company has established its primary research facility in 8,215 square feet of leased office and laboratory space in Oceanside, California. The lease for this facility expires in August 2016. The current base rent is $8,588 per month. The facility has leasehold improvements which include cGMP (current Good Manufacturing Practices) level clean rooms designed for the derivation of clinical-grade stem cells and their differentiated derivatives, research laboratories for the Company’s stem cell differentiation studies and segregated rooms for biohazard control and containment of human donor tissue. The monthly base rent will increase by 3% annually on the anniversary date of the agreement.
	The Company leases a 5,520 square foot manufacturing facility in Frederick, Maryland, which is used for laboratory and administrative purposes. The current base rent is $11,032. The initial term of the lease expires in December 2015 and there is an option for an additional five years. The laboratory is being used to develop and manufacture the Company’s research products and the administration facility is used for sales and marketing and general administrative purposes. The manufacturing laboratory space has clean rooms and is fitted with the necessary water purification, refrigeration, labeling equipment and standard manufacturing equipment to manufacture, package, store, and distribute media products.
	On February 25, 2011, the Company entered into a lease agreement (the “Lease Agreement”) with S Real Estate Holdings LLC to allow the Company to expand into new corporate offices located at 5950 Priestly Drive, Carlsbad, California. The building is used for administrative purposes, but could also be used for research and development purposes if such space is needed in the future. The lease initially covered approximately 4,653 square feet, starting on March 1, 2011, and was amended to cover approximately 8,199 square feet effective July 1, 2011, and to cover approximately 9,848 square feet effective January 1, 2013. The lease expires on February 29, 2016, subject to the Company’s right to extend the term for up to five additional years. The Company began paying rent at an initial rate of $5,118 per month and the rate was amended effective July 1, 2011 and January 1, 2013 to account for additional square footage occupied by the Company. The current base rent is $11,837 per month. The monthly base rent will increase by 3% annually on the anniversary date of the agreement. The Company is also obligated to pay a portion of the utilities for the building and increases in property tax and insurance.
	S Real Estate Holdings LLC is owned by Dr. Ruslan Semechkin, the Company’s Chief Scientific Officer and a director, and was previously owned by Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors. The Lease Agreement was negotiated at arm’s length and was reviewed by the Company’s outside legal counsel. The terms of the lease were reviewed by a committee of independent directors, and the Company believes that, in total, those terms are consistent with the terms that could be obtained for comparable facilities from an unaffiliated party.
	The Company incurred rent expense of $79,000 and $84,000 for the three months ended June 30, 2014 and 2013, respectively. For the six months ended June 30, 2014 and 2013, the Company incurred rent expense of $158,000.
	Future minimum lease payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2014, are as follows (in thousands):
		Amount
	2014 (remaining six months)	$	194
	2015		397
	2016		101
	2017		3
	Total	$	695
	Marketing Agreement
	In September 2011, the Company signed a Marketing Agreement (“agreement”) with an effective date of June 30, 2011, superseding the terms of a previous arrangement with a third party marketing organization. According to the agreement, the third party marketing organization will continue to provide assistance to Lifeline Skin Care, Inc., (“LSC”) a wholly-owned subsidiary of International Stem Cell, to sell skin care products through various specific proprietary mailings. In exchange for such services, the Company will pay 20% of net revenues for Direct Sales (as defined in the agreement) generated from the proprietary mailings. In addition, the Company agreed to pay 10% of net revenues for Referral Sales. The agreement specifies that the parties do not intend to create a joint venture, and that either party may terminate the agreement upon 30-day written notice. In addition, the agreement provided for two tranches of common stock warrants issued by the Company for the benefit of the third party marketing organization for 100,000 shares each, with strike prices of $1.50 and $2.00, respectively, with vesting over four quarters, and warrant term of five years. Subsequently in July 2012, the Company renegotiated the commission structure to reflect slightly lower rates, 18% on net revenues derived from direct sales and 9% on net revenues derived from referral sales. LSC incurred $10,000 and $19,000 as commission expenses during the three months ended June 30, 2014 and 2013, respectively, under the terms of this agreement. For the six months ended June 30, 2014 and 2013, the commission expense incurred under this agreement was $23,000 and 43,000, respectively.
	Customer Concentration
	During the three and six months ended June 30, 2014 for the Biomedical market segment, one customer accounted for 19% and 20% of consolidated revenues. During the three and six months ended June 30, 2013 for the Biomedical market segment, one customer accounted for 14% and 15% of our consolidated revenues. No other single customer accounted for more than 10% of revenues for any period presented.

Segments_and_Geographic_Inform

Segments and Geographic Information	6 Months Ended
	Jun. 30, 2014
Segments and Geographic Information	'
	11. Segments and Geographic Information
	The Company’s chief operating decision-maker reviews financial information presented on a consolidated basis, accompanied by disaggregated information by each reportable company’s statement of operations. The Company operates the business on the basis of three reporting segments, the parent company and two wholly-owned subsidiaries:
	International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of hpSCs for the treatment of various diseases such as Parkinson’s disease, liver diseases and corneal blindness;
	Lifeline Skin Care, Inc. for the Cosmeceutical Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells;
	Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products including over 130 human cell culture products, including frozen human “primary” cells and the reagents (called “media”) needed to grow, maintain and differentiate the cells.
	Revenues, Expenses and Operating Income (loss)
	The Company does not measure the performance of its segments on any asset-based metrics. Therefore, segment information is presented only for operating income (loss). Revenues, expenses and operating income (loss) by market segment were as follows (in thousands):
		For the Three Months						For the Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014			2013
	Revenues:
	Cosmeceutical market	$	746		$	709		$	1,549		$	1,359
	Biomedical market		842			748			1,688			1,383
	Total revenues		1,588			1,457			3,237			2,742
	Operating expenses:
	Therapeutic market		2,388			2,329			4,608			4,171
	Cosmeceutical market		785			738			1,573			1,341
	Biomedical market		658			580			1,364			1,134
	Total operating expenses		3,831			3,647			7,545			6,646
	Operating income (loss):
	Therapeutic market		(2,388	)		(2,329	)		(4,608	)		(4,171	)
	Cosmeceutical market		(39	)		(29	)		(24	)		18
	Biomedical market		184			168			324			249
	Total operating income (loss)	$	(2,243	)	$	(2,190	)	$	(4,308	)	$	(3,904	)
	Geographic Information
	The Company’s wholly-owned subsidiaries are located in Maryland and California, and have customer and vendor relationships worldwide. Significant revenues in the following regions are those that are attributable to the individual countries within the region to which the product was shipped (in thousands):
		For the Three Months Ended						For the Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	North America	$	1,318		$	1,064		$	2,667		$	2,082
	Asia		162			294			340			421
	Europe		101			77			210			188
	All other regions		7			22			20			51
	Total	$	1,588		$	1,457		$	3,237		$	2,742

Subsequent_Event

Subsequent Event	6 Months Ended
	Jun. 30, 2014
Subsequent Event	'
	12. Subsequent Event
	On August 6, 2014 to obtain funding for working capital purposes, the Company entered into a securities purchase agreement with Dr. Andrey Semechkin and Dr. Ruslan Semechkin to sell a total of 6,000,000 shares of common stock at a price of $0.10 per share, for a total purchase price of $600,000. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer. Dr. Ruslan Semechkin is the Company’s Chief Scientific Officer and director.

Organization_and_Significant_A1

Organization and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Business Combination and Corporate Restructure	'
	Business Combination and Corporate Restructure
	BTHC III, Inc. (“BTHC III” or the “Company”) was organized in Delaware in June 2005 as a shell company to effect the reincorporation of BTHC III, LLC, a Texas limited liability company. On December 28, 2006, the Company effected a Share Exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation, a California corporation (“ISC California”). After giving effect to the Share Exchange, the stockholders of ISC California owned 93.7% of issued and outstanding shares of common stock. As a result of the Share Exchange, ISC California is now the wholly-owned subsidiary, though for accounting purposes it was deemed to have been the acquirer in a “reverse merger.” In the reverse merger, BTHC III is considered the legal acquirer and ISC California is considered the accounting acquirer. On January 29, 2007, the Company changed its name from BTHC III, Inc. to International Stem Cell Corporation.
	Lifeline Cell Technology, LLC (“LCT”) was formed in the State of California on August 17, 2001. LCT is in the business of developing and manufacturing purified primary human cells and optimized reagents for cell culture. LCT’s scientists have used a technology, called basal medium optimization, to systematically produce products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. LCT distinguishes itself in the industry by having in place scientific and manufacturing staff with the experience and knowledge to set up systems and facilities to produce a source of consistent, standardized, non-human animal protein free cell products, some of which are suitable for FDA approval.
	On July 1, 2006, LCT entered into an agreement among LCT, ISC California and the holders of membership units and warrants. Pursuant to the terms of the agreement, all the membership units in LCT were exchanged for 20,000,000 shares of ISC California Common Stock and for ISC California’s assumption of LCT’s obligations under the warrants. LCT became a wholly-owned subsidiary of ISC California.
	Lifeline Skin Care, Inc. (“LSC”) was formed in the State of California on June 5, 2009 and is a wholly-owned subsidiary of ISC California. LSC develops, manufactures and markets cosmeceutical products, utilizing an extract derived from the Company’s human parthenogenetic stem cell technologies.
Going Concern	'
	Going Concern
	The Company needs to raise additional working capital. The timing and degree of any future capital requirements will depend on many factors. Currently, the Company’s burn rate is approximately $560,000 per month, excluding capital expenditures and patent costs averaging $93,000 per month. There can be no assurance that the Company will be successful in maintaining its normal operating cash flow, and that such cash flows will be sufficient to sustain the Company’s operations through 2014. Based on the above, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements were prepared assuming that the Company is a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
	Management’s plans in regard to these matters are focused on managing its cash flow, the proper timing of its capital expenditures, and raising additional capital or financing in the future. In December 2013, the Company filed a registration statement with the Securities Exchange Commission (the “SEC”), which allows the Company to sell up to $10,250,000 of common stock to Lincoln Park Capital Fund, LLC (“Lincoln Park”) from time to time through January 2017 at the Company’s discretion. The registration statement was declared effective on January 13, 2014. However, the Company cannot predict the timing or amount of any funds that it may actually receive, and as part of the June 2014 warrant exchange transaction discussed below, the Company agreed that until September 14, 2014 it would not issue additional shares in capital raising transactions other than in private placements to its officers and directors. During the six months ended June 30, 2014, to obtain funding for working capital purposes, the Company sold a total of 8,200,000 shares of common stock under the stock Purchase Agreement with Lincoln Park, raising approximately $1,588,000. For further discussion, see Note 6, Capital Stock.
	During the second quarter of 2014, the Company sold an additional 8,833,333 shares of common stock to the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors, Dr. Andrey Semechkin, and Dr. Ruslan Semechkin, Chief Scientific Officer and a director, for an aggregate of $1,050,000, as discussed in Note 6, Capital Stock.
Basis of Presentation	'
	Basis of Presentation
	The Company is a biotechnology company focused on therapeutic and clinical product development with multiple long-term therapeutic opportunities and two revenue-generating subsidiaries with potential for increased future revenues. The Company was in the development stage from inception through the quarter ended September 30, 2013. During the quarter ended December 31, 2013, the Company exited the development stage based on a consistent, increasing revenue trend and more significant revenue generated from its two commercial businesses. The Company generated product revenues from the two commercial businesses of $6,147,000 for the year ended December 31, 2013. The Company currently has no revenue generated from its principal operations in therapeutic and clinical product development.
	The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q.
	These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to consolidated financial statements included in the annual report on Form 10-K of International Stem Cell Corporation and Subsidiaries for the year ended December 31, 2013. When used in these notes, the terms “Company,” “we,” “us,” or “our” mean International Stem Cell Corporation and all entities included in the unaudited condensed consolidated financial statements.
	In the opinion of management, the unaudited condensed consolidated financial information for the interim periods presented reflects all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the Company’s consolidated results of operations, financial position and cash flows. The unaudited condensed consolidated financial statements and the related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2013 included in the Company’s annual report on Form 10-K. Operating results for interim periods are not necessarily indicative of the operating results for any other interim period or an entire year.
Principles of Consolidation	'
	Principles of Consolidation
	The Company’s consolidated financial statements include the accounts of International Stem Cell Corporation and its subsidiaries after intercompany balances and transactions have been eliminated.
Reclassification	'
	Reclassification
	Certain amounts within the unaudited condensed consolidated statements of operations for the prior period have been reclassified to conform to the current period presentation. These reclassifications had no impact on the Company’s previously reported results of operations.
Cash Equivalents	'
	Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Restricted Cash	'
	Restricted Cash
	The Company is required to maintain $50,000 in a restricted certificate of deposit account in order to fully collateralize two revolving credit card accounts.
Inventories	'
	Inventories
	Inventories are accounted for using the first-in, first-out (FIFO) method for LSC products, and specific identification method for LCT products. Inventory balances are stated at the lower of cost or market. Laboratory supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolescence and is adjusted accordingly.
Accounts Receivable	'
	Accounts Receivable
	Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable primarily consist of trade accounts receivable from the sales of LCT’s products, timing of cash receipts by the Company related to LSC credit card sales to customers, as well as LSC trade receivable amounts related to spa and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to accounts receivable and reserves specific amounts if collectability is no longer reasonably assured. As of June 30, 2014 and December 31, 2013, the Company had an allowance for bad debt totaling $19,000.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over five years. The costs of major remodeling and leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the life of the asset.
Intangible Assets	'
	Intangible Assets
	Intangible assets consist of acquired research and development rights used in research and development, and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents. Patent or patent license amortization only begins once a patent license is acquired or a patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and patent licenses are recorded at cost and are amortized on a straight-line basis over the shorter of the lives of the underlying patents or the useful life of the license.
Long-Lived Asset Impairment	'
	Long-Lived Asset Impairment
	The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered, and at least annually. The Company considers assets to be impaired and writes them down to fair value if expected associated undiscounted cash flows are less than the carrying amounts. Fair value is the present value of the associated cash flows. The Company did not recognize material impairments on its long-lived assets during the three and six months ended June 30, 2014 and 2013.
Product Sales	'
	Product Sales
	The Company recognizes revenue from product sales at the time of shipment to the customer, provided no significant obligations remain and collection of the receivable is reasonably assured. If the customer has a right of return, the Company recognizes product revenues upon shipment, provided that future returns can be reasonably estimated. In the case where returns cannot be reasonably estimated, revenue will be deferred until such estimates can be made or the right of return has lapsed. LCT contributed 52% and 50% of total revenue during the six months ended June 30, 2014 and 2013, respectively. LSC contributed 48% and 50% of total revenue during the six months ended June 30, 2014 and 2013, respectively.
Deferred Revenue and Allowance for Sales Returns	'
	Deferred Revenue and Allowance for Sales Returns
	The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed or determinable, and collectability is reasonably assured. However, the LSC products have a 30-day product return guarantee for website sales. The Company has estimated the historical rate of returns for the 30-day product return guarantee, which has remained consistent for the three and six months ended June 30, 2014 as compared to the years ended December 31, 2013 and 2012. At June 30, 2014 and December 31, 2013, the estimated allowance for sales returns was $10,000. At June 30, 2014 and December 31, 2013, net deferred revenue totaled $0 and $3,000, respectively.
Cost of Sales	'
	Cost of Sales
	Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products and include related direct materials, general laboratory supplies and allocation of overhead. Certain of the agreements under which the Company has licensed technology will require the payment of royalties based on the sale of its future products. Such royalties will be recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to developed technologies used in the Company’s products will be classified as a component of cost of sales to the extent such payments become due in the future.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs, which are expensed as incurred, are primarily comprised of costs and expenses for salaries and benefits associated with research and development personnel, overhead and occupancy, contract services, and amortization of license costs for technology used in research and development with alternative future uses.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company recognized stock-based compensation expense associated with stock options and other stock-based awards in accordance with the authoritative guidance for stock-based compensation. The cost of a stock-based award is measured at the grant date based on the estimated fair value of the award, and is recognized as expense on a straight-line basis, net of estimated forfeitures over the requisite service period of the award. The fair value of stock options is estimated using the Black-Scholes option valuation model, which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. The fair value of restricted stock awards is based on the market value of our common stock on the date of grant.
Fair Value Measurements	'
	Fair Value Measurements
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
	Level 1		Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2	Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3	Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of June 30, 2014 (in thousands):
		Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents	$	5		$	5	$	—	$	—
	LIABILITIES:
	Warrants to purchase common stock	$	—		$	—	$	—	$	—
	The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2013 (in thousands):
		Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents	$	5		$	5	$	—	$	—
	LIABILITIES:
	Warrants to purchase common stock	$	4,925		$	—	$	—	$	4,925
	The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands):
		Warrants to purchase
		common stock
	Beginning balance at December 31, 2012	$	—
	Issuances of warrants		5,986
	Exercise of warrants		(1,815	)
	Adjustments to estimated fair value		754
	Ending balance at December 31, 2013		4,925
	Issuances of warrants		—
	Exercise of warrants		—
	Adjustments to estimated fair value		(1,894	)
	Warrants exchanged for common stock		(3,031	)
	Ending balance at June 30, 2014	$	—
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes in accordance with applicable authoritative guidance, which requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options, as well as the Monte-Carlo valuation method for certain warrants. Actual results could differ from those estimates.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company believes that the carrying value of its cash and cash equivalents, receivables, accounts payable and accrued liabilities as of June 30, 2014 and December 31, 2013 approximate their fair values because of the short-term nature of those instruments. The fair value of certain warrants was determined at each quarterly reporting date as necessary using the Monte-Carlo valuation methodology.
Income (Loss) Per Common Share	'
	Income (Loss) Per Common Share
	The computation of net loss per common share is based on the weighted average number of shares outstanding during each period. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. At June 30, 2014, there were 472,500 non-vested restricted stock awards, 20,236,077 vested and 7,082,333 non-vested stock options outstanding, and 7,762,500 warrants outstanding, which were convertible into 7,762,500 shares of common stock; and at June 30, 2013, there were 660,000 non-vested restricted stock awards, 16,916,733 vested and 6,846,560 non-vested stock options outstanding, and 9,462,500 warrants outstanding, which were convertible into 9,462,500 shares of common stock. These restricted stock awards, stock options and warrants were not included in the diluted loss per share calculation because the effect would have been anti-dilutive.
Comprehensive Income	'
	Comprehensive Income
	Comprehensive income or loss includes all changes in equity except those resulting from investments by owners and distributions to owners. The Company did not have any items of comprehensive income or loss other than net loss from operations for the three and six months ended June 30, 2014 and 2013.
Registration Payment Arrangements	'
	Registration Payment Arrangements
	In accordance with applicable authoritative guidance, the Company is required to separately recognize and measure registration payment arrangements, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement. Such payments include penalties for failure to effect a registration of securities.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers.  The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective.  The new standard is effective for the Company on January 1, 2017.  Early application is not permitted.  The standard permits the use of either the retrospective or cumulative effect transition method.  The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures.  The Company has not yet selected a transition method nor has it determined the effect of the standard on it ongoing financial reporting.
	In July 2013, the FASB issued an accounting standards update that provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company has adopted this guidance at the beginning of the first quarter of fiscal year 2014. The adoption of this standard does not have a material impact on the Company’s financial position, results of operations or related financial statement disclosures.

Organization_and_Significant_A2

Organization and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Values of Assets and Liabilities	'
	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of June 30, 2014 (in thousands):
		Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents	$	5		$	5	$	—	$	—
	LIABILITIES:
	Warrants to purchase common stock	$	—		$	—	$	—	$	—
	The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2013 (in thousands):
		Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents	$	5		$	5	$	—	$	—
	LIABILITIES:
	Warrants to purchase common stock	$	4,925		$	—	$	—	$	4,925
Fair Value Measurement and Unobservable Rollforward Activity of Liabilities	'
	The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) (in thousands):
		Warrants to purchase
		common stock
	Beginning balance at December 31, 2012	$	—
	Issuances of warrants		5,986
	Exercise of warrants		(1,815	)
	Adjustments to estimated fair value		754
	Ending balance at December 31, 2013		4,925
	Issuances of warrants		—
	Exercise of warrants		—
	Adjustments to estimated fair value		(1,894	)
	Warrants exchanged for common stock		(3,031	)
	Ending balance at June 30, 2014	$	—

Inventory_Tables

Inventory (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of the Components of Inventories	'
	The components of inventories are as follows (in thousands):
		June 30,			December 31,
		2014			2013
	Raw materials	$	242		$	147
	Work in process		497			446
	Finished goods		867			902
	Total		1,606			1,495
	Less: allowance for inventory obsolescence		(136	)		(126	)
	Inventory, net	$	1,470		$	1,369

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Property and Equipment	'
	Property and equipment consists of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Machinery and equipment		1,347		$	1,170
	Computer equipment		250			246
	Office equipment		203			203
	Leasehold improvements		757			745
	Construction in progress		25			—
			2,582			2,364
	Less: accumulated depreciation and amortization		(1,735	)		(1,534	)
	Property and equipment, net	$	847		$	830

Patent_Licenses_Tables

Patent Licenses (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Future Amortization Expense Related to Intangible Assets Subject to Amortization	'
	At June 30, 2014, future amortization expense related to intangible assets subject to amortization is expected to be as follows (in thousands):
		Amount
	2014 (remaining six months)	$	31
	2015		62
	2016		62
	2017		62
	2018		62
	Thereafter		2,200
	Total	$	2,479

Advances_Tables

Advances (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Advances from Nonaffiliated Collaboration	'
	As of June 30, 2014 no revenues were realized from this agreement.
		June 30,		December 31,
		2014		2013
	BioTime, Inc. (in thousands)	$	250	$	250

Capital_Stock_Tables

Capital Stock (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Shares of Common Stock Reserved for Future Issuance	'
	At June 30, 2014, the Company had shares of common stock reserved for future issuance as follows:
	Options outstanding	27,318,410
	Options available for future grant	8,396,333
	Convertible preferred stock	88,634,236
	Warrants	7,762,500
		132,111,479

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Total Stock-Based Compensation Expense	'
	Total stock-based compensation expense for the three and six months ended June 30, 2014 and 2013 was comprised of the following (in thousands):
		Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
		June 30,			June 30,			June 30,			June 30,
		2014			2013			2014			2013
	Cost of sales	$	15		$	—		$	30		$	—
	Research and development		73			93			143			177
	Selling and marketing		12			10			23			19
	General and administrative		274			337			525			653
		$	374		$	440		$	721		$	849
Fair Value of Stock Option Award, Weighted Average Assumptions	'
	The fair value of options granted is estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended					Three Months Ended					Six Months Ended							Six Months Ended
		June 30,					June 30,					June 30,							June 30,
		2014					2013					2014							2013
	Significant assumptions (weighted average):
	Risk-free interest rate at grant date		1.91	%				0.95	%					1.91	%						0.95	%
	Expected stock price volatility		99.72	%				118.34	%					99.72	%						118.34	%
	Expected dividend payout		0	%				0	%					0	%						0	%
	Expected option life based on management's estimate	6.1 yrs					6.1 yrs					6.1 yrs							6.1 yrs
Summary of Changes in Options Outstanding and Related Exercise Prices for Shares of Company's Common Stock Options Issued	'
	Transactions involving stock options issued to employees, directors and consultants under the 2006 Plan, the 2010 Plan and outside the plans are summarized below. Options issued have a maximum life of 10 years. The following tables summarize the changes in options outstanding and the related exercise prices for the Company’s common stock options issued:
		Number of													Weighted
		Shares Issued					Weighted								Average						Aggregate
		Under					Average Exercise								Remaining						Intrinsic
		2006 Plan and					Price Per								Contractual						Value
		2010 Plan					Share								Term						(in thousands)
	Outstanding at December 31, 2012		15,122,900				$	1.18
	Granted		1,491,500				$	0.26
	Exercised		—				$	—
	Canceled or expired		(586,000	)			$	0.61
	Outstanding at December 31, 2013		16,028,400				$	1.12
	Granted		4,104,000				$	0.16
	Exercised		—				$	—
	Canceled or expired		(423,283	)			$	0.72
	Outstanding at June 30, 2014		19,709,117				$	0.93							6.72 years						$			—
	Vested and expected to vest at June 30, 2014		18,704,421				$	0.97							6.57 years						$			—
	Exercisable at June 30, 2014		12,626,784				$	1.2							5.48 years						$			—
													Weighted
		Number of					Weighted					Average				Aggregate
		Shares Issued					Average Exercise					Remaining				Intrinsic
		Outside					Price Per					Contractual				Value
		the Plan					Share					Term				(in thousands)
	Outstanding at December 31, 2012		8,254,232				$	0.65
	Granted		—				$	—
	Exercised		—				$	—
	Canceled or expired		(644,939	)			$	1
	Outstanding at December 31, 2013		7,609,293				$	0.62
	Granted		—				$	—
	Exercised		—				$	—
	Canceled or expired		—				$	—
	Outstanding, vested and exercisable at June 30, 2014		7,609,293				$	0.62					5.36 years				$	—
Summary of Changes in Restricted Stock Award Activity	'
	The following table summarizes the changes in restricted stock award activity and the related weighted average exercise prices for the Company’s awards issued:
		Restricted
		Stock Issued
		from the			Weighted
		2006 Plan and			Average Grant Date
		2010 Plan			Fair Value
	Unvested at December 31, 2012		335,000		$	0.32
	Granted		961,000		$	0.24
	Vested		(1,029,750	)	$	0.27
	Forfeited		(121,250	)	$	0.25
	Unvested at December 31, 2013		145,000		$	0.23
	Granted		716,500		$	0.21
	Vested		(388,750	)	$	0.23
	Forfeited		—		$	—
	Unvested at June 30, 2014		472,750		$	0.2
Summary of Outstanding Warrants Related to Warrant Transactions	'
	Share data related to warrant transactions through June 30, 2014 were as follows:
		Preferred Stock						Common Stock							Units				Common Stock													Price per Warrant
																																		Weighted
															Placement				YKA				Skin Care		Jan-13		Mar-13		Total					Average
		Series A			Series B			Series A			Series B				Agent				Loan				Marketing		Financing		Financing		Warrants			Range		Exercise Price
	Outstanding,		1,600,000			300,000			—			—				—				1,400,000				200,000		—		—		3,500,000		$	0.25-2.00	$	0.336
	December 31, 2012
	2013
	Issued								36,754,822			20,000,000				666,666										5,062,500		2,500,000		64,983,988		$	0.15-0.200	$	0.156
	Exercised								(200,000	)		(16,754,822	)																	(16,954,822	)	$	0.145-0.15	$	0.147
	Forfeited/Cancelled		(1,600,000	)		(300,000	)					(3,245,178	)							(1,400,000	)									(6,545,178	)	$	0.15-0.250	$	0.198
	Outstanding,		—			—			36,554,822			—				666,666				—				200,000		5,062,500		2,500,000		44,983,988		$	0.145-2.00	$	0.166
	December 31, 2013
	2014
	Issued																													—
	Exchanged								(36,554,822	)						(666,666	)													(37,221,488	)	$	0.15	$	0.15
	Exercised																													—
	Forfeited/Cancelled																													—
	Outstanding,		—			—			—			—				—				—				200,000		5,062,500		2,500,000		7,762,500		$	0.145-2.00	$	0.24
	June 30, 2014

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Future Minimum Lease Payments Required under Operating Leases that Have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year	'
	Future minimum lease payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2014, are as follows (in thousands):
		Amount
	2014 (remaining six months)	$	194
	2015		397
	2016		101
	2017		3
	Total	$	695

Segments_and_Geographic_Inform1

Segments and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2014
Revenues, Expenses and Operating Income (Loss) by Market Segment	'
	Revenues, expenses and operating income (loss) by market segment were as follows (in thousands):
		For the Three Months						For the Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014			2013
	Revenues:
	Cosmeceutical market	$	746		$	709		$	1,549		$	1,359
	Biomedical market		842			748			1,688			1,383
	Total revenues		1,588			1,457			3,237			2,742
	Operating expenses:
	Therapeutic market		2,388			2,329			4,608			4,171
	Cosmeceutical market		785			738			1,573			1,341
	Biomedical market		658			580			1,364			1,134
	Total operating expenses		3,831			3,647			7,545			6,646
	Operating income (loss):
	Therapeutic market		(2,388	)		(2,329	)		(4,608	)		(4,171	)
	Cosmeceutical market		(39	)		(29	)		(24	)		18
	Biomedical market		184			168			324			249
	Total operating income (loss)	$	(2,243	)	$	(2,190	)	$	(4,308	)	$	(3,904	)
Summary of Significant Revenues in Following Regions	'
	Significant revenues in the following regions are those that are attributable to the individual countries within the region to which the product was shipped (in thousands):
		For the Three Months Ended						For the Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	North America	$	1,318		$	1,064		$	2,667		$	2,082
	Asia		162			294			340			421
	Europe		101			77			210			188
	All other regions		7			22			20			51
	Total	$	1,588		$	1,457		$	3,237		$	2,742

Organization_and_Significant_A3

Organization and Significant Accounting Policies - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

Jul. 19, 2013

Mar. 12, 2013

Jan. 22, 2013

Jun. 26, 2014

29-May-14

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jul. 01, 2006

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 11, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 16, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Restricted Stock [Member]

Restricted Stock [Member]

Warrants [Member]

Warrants [Member]

Allowance for Sales Returns [Member]

Allowance for Sales Returns [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Cell Technology [Member]

Cell Technology [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Organization And Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of ownership in issued and outstanding shares of common stock parent Company

'

'

'

'

'

'

93.70%

'

93.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock in subsidiary Company

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Burn rate

'

'

'

'

'

'

'

'

$560,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital expenditures and patent costs

'

'

'

'

'

'

'

'

93,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential common stock value to be sold

'

'

'

'

'

10,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,250,000

'

'

'

'

'

'

'

'

'

Number of shares of common stock sold

'

5,000,000

10,125,000

5,500,000

3,333,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,866,666

1,666,666

3,000,000

8,200,000

'

'

'

'

'

'

'

Common stock sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,838,000

250,000

'

1,588,000

'

'

'

'

'

'

'

Common stock, shares issued

'

'

'

'

'

151,175,053

213,590,669

'

213,590,669

'

151,175,053

'

'

'

'

'

'

'

'

'

'

'

'

'

8,833,333

'

'

'

'

'

Proceeds from issuance of common stock

2,377,000

1,000,000

2,025,000

550,000

500,000

'

'

'

2,638,000

3,289,000

'

'

'

'

'

'

'

'

'

'

'

484,000

1,588,000

'

1,050,000

'

'

'

'

'

Revenues

'

'

'

'

'

'

1,588,000

1,457,000

3,237,000

2,742,000

6,147,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash

'

'

'

'

'

50,000

50,000

'

50,000

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allowance for doubtful accounts

'

'

'

'

'

19,000

19,000

'

19,000

'

19,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful life of property and equipment

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of revenue contributed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

48.00%

50.00%

'

52.00%

50.00%

Period of right of return guarantee

'

'

'

'

'

'

'

'

'

'

'30 days

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allowance for sales returns

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

10,000

'

'

'

'

'

'

'

'

'

'

'

Net deferred revenue

'

'

'

'

'

$3,000

$0

'

$0

'

$3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-vested restricted stock awards

'

'

'

'

'

'

'

'

'

'

'

'

'

472,500

660,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested stock options outstanding

'

'

'

'

'

'

'

'

20,236,077

16,916,733

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options outstanding, non-vested

'

'

'

'

'

'

7,082,333

6,846,560

7,082,333

6,846,560

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding convertible into common stock

'

2,500,000

5,062,500

'

'

'

7,762,500

9,462,500

7,762,500

9,462,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

'

'

'

'

'

44,983,988

7,762,500

'

7,762,500

'

44,983,988

3,500,000

'

'

'

7,762,500

9,462,500

'

'

'

'

'

'

10,088,154

'

200,000

'

200,000

'

'

Organization_and_Significant_A4

Organization and Significant Accounting Policies - Fair Values of Assets and Liabilities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ASSETS:	'	'
Cash equivalents	$5	$5
LIABILITIES:	'	'
Warrants to purchase common stock	'	4,925
Level 1 [Member]	'	'
ASSETS:	'	'
Cash equivalents	5	5
LIABILITIES:	'	'
Warrants to purchase common stock	'	'
Level 2 [Member]	'	'
LIABILITIES:	'	'
Warrants to purchase common stock	'	'
Level 3 [Member]	'	'
LIABILITIES:	'	'
Warrants to purchase common stock	'	$4,925

Organization_and_Significant_A5

Organization and Significant Accounting Policies - Fair Value Measurement and Unobservable Rollforward Activity of Liabilities (Detail) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
Ending balance	'	$4,925
Warrants [Member]	'	'
Fair Value Disclosures [Abstract]	'	'
Beginning balance	4,925	'
Issuances of warrants	'	5,986
Exercise of warrants	'	-1,815
Adjustments to estimated fair value	-1,894	754
Warrants exchanged for common stock	-3,031	'
Ending balance	'	$4,925

Inventory_Summary_of_the_Compo

Inventory - Summary of the Components of Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$242	$147
Work in process	497	446
Finished goods	867	902
Total	1,606	1,495
Less: allowance for inventory obsolescence	-136	-126
Inventory, net	$1,470	$1,369

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	$2,582	$2,364
Less: accumulated depreciation and amortization	-1,735	-1,534
Property and equipment, net	847	830
Machinery and Equipment [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	1,347	1,170
Computer Equipment [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	250	246
Office Equipment [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	203	203
Leasehold Improvements [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	757	745
Construction in Progress	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	$25	'

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property Plant And Equipment [Abstract]	'	'	'	'
Depreciation expense	$101,000	$100,000	$202,000	$201,000

Patent_Licenses_Additional_Inf

Patent Licenses - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Jun. 30, 2014

Dec. 31, 2013

14-May-04

Feb. 13, 2004

Dec. 31, 2003

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Feb. 07, 2013

Dec. 31, 2013

Dec. 31, 2012

Feb. 07, 2013

Feb. 07, 2013

Jun. 30, 2014

UMass IP [Member]

UMass IP [Member]

UMass IP [Member]

UMass IP [Member]

UMass IP [Member]

ACT IP [Member]

Installment

Minimum [Member]

Maximum [Member]

Finite Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option and license fees

$3,020,000

$2,760,000

$400,000

$22,500

$340,000

'

'

'

'

'

'

'

'

'

'

Obligation to pay royalties (Ranged)

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

12.00%

'

Royalties percentage of net sales

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

Minimum annual license fee

'

'

'

'

'

'

'

'

'

'

150,000

75,000

'

'

'

Number of installments

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

Patent acquisition costs

2,273,000

'

'

'

'

2,273,000

'

2,273,000

'

'

'

'

'

'

747,000

Amortization expense

'

'

'

'

'

16,000

15,000

32,000

30,000

'

'

'

'

'

'

Accumulated amortization

$542,000

$510,000

'

'

'

$542,000

'

$542,000

'

'

'

'

'

'

'

Patent_Licenses_Summary_of_Fut

Patent Licenses - Summary of Future Amortization Expense Related to Intangible Assets Subject to Amortization (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
2014 (remaining six months)	$31
2015	62
2016	62
2017	62
2018	62
Thereafter	2,200
Total	$2,479

Advances_Additional_Informatio

Advances - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 18, 2008
Advances [Abstract]	'	'	'
Advances from nonaffiliated collaboration	$250,000	$250,000	$250,000
Specified amount of revenue to be utilized for advances	'	'	250,000
Revenue realized from agreement	$0	'	'

Advances_Schedule_of_Advances_

Advances - Schedule of Advances from Nonaffiliated Collaboration (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 18, 2008
Advances [Line Items]	'	'	'
Advances from nonaffiliated collaboration	$250,000	$250,000	$250,000

Capital_Stock_Additional_Infor

Capital Stock - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jul. 19, 2013
Equity [Abstract]	'	'	'
Common stock, shares authorized	600,000,000	300,000,000	'
Preferred stock, shares authorized	20,000,000	20,000,000	'
Common stock, par value	$0.00	$0.00	$0.00
Preferred stock, par value	$0.00	$0.00	'

Capital_Stock_Series_B_Preferr

Capital Stock - Series B Preferred Stock Transactions - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Mar. 12, 2013

Jan. 22, 2013

12-May-08

Dec. 31, 2013

Mar. 31, 2013

Jun. 30, 2014

Aug. 31, 2013

Jul. 31, 2013

12-May-08

Mar. 31, 2013

12-May-08

Dec. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

31-May-08

Jun. 30, 2014

Dec. 31, 2008

Jul. 24, 2013

12-May-08

Investor

Series B Warrants [Member]

Common Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Common Stock [Member]

Class Of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of accredited investors

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of units issued

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

Number of Series B Preferred Stock for each Series B unit

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

1

'

'

Number of warrants to purchase common stock

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

Common stock purchase price, per share

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

Proceeds from issuance of preferred stock and warrants

'

'

'

'

'

'

'

'

'

'

$400,000

'

'

'

'

'

'

'

'

Conversion ratio for each share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

Initial conversion price

'

'

'

'

'

'

'

'

'

'

$0.50

'

'

'

'

'

'

'

'

Warrants exercisable price

0.2

0.2

'

'

'

'

0.25

0.15

'

'

0.5

'

'

'

'

'

'

0.15

'

Number of years from issuance of warrants to convert as common stock

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

Convertible preferred stock, conversion price

'

'

'

$0.15

$0.20

$0.07

'

'

'

'

'

$0.15

$0.15

$0.20

'

$0.07

'

'

'

Liquidation premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

Preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

300,000

'

'

'

Preferred stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

300,000

'

'

'

Issuance price per share

$0.20

$0.20

'

'

'

'

'

'

'

$0.20

'

'

'

'

'

'

'

'

'

Capital_Stock_Series_C_Preferr

Capital Stock - Series C Preferred Stock Transactions - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

Mar. 12, 2013

Jan. 22, 2013

Jun. 26, 2014

29-May-14

Dec. 31, 2013

Mar. 31, 2013

Jun. 30, 2014

Jan. 22, 2013

Mar. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Sep. 23, 2008

Aug. 20, 2008

Jun. 30, 2014

Dec. 31, 2013

Jan. 22, 2013

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Class Of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock sold

5,000,000

10,125,000

5,500,000

3,333,333

'

'

'

'

'

17,033,000

37,991,000

1,300,000

700,000

'

'

'

Issuance price per share

$0.20

$0.20

'

'

'

'

'

'

$0.20

'

'

$1

'

'

'

'

Convertible preferred stock, conversion price

'

'

'

'

$0.15

$0.20

$0.07

'

'

'

'

'

$0.25

'

'

'

Preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

Preferred stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

Convertible shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.25

Issuance of common stock from conversion of Series C preferred stock, shares

'

'

'

'

'

'

'

8,000,000

'

'

8,000,000

'

'

'

'

'

Capital_Stock_Series_D_Preferr

Capital Stock - Series D Preferred Stock Transactions - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Mar. 12, 2013

Jan. 22, 2013

Jun. 26, 2014

29-May-14

Dec. 31, 2013

Mar. 31, 2013

Jun. 30, 2014

Mar. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Dec. 30, 2008

Jun. 30, 2014

Dec. 31, 2013

Dec. 30, 2008

Dec. 30, 2008

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

X-Master Inc. [Member]

Dr. Andrey Semechkin [Member]

Class Of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock sold

5,000,000

10,125,000

5,500,000

3,333,333

'

'

'

'

17,033,000

37,991,000

43

'

'

10

33

Total proceeds

'

'

'

'

'

'

'

'

'

'

$4,700,000

'

'

'

'

Issuance price per share

$0.20

$0.20

'

'

'

'

'

$0.20

'

'

$100,000

'

'

'

'

Preferred stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

43

43

'

'

Convertible preferred stock, conversion price

'

'

'

'

$0.15

$0.20

$0.07

'

'

'

'

'

'

'

'

Issuance price per share

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

Capital_Stock_Series_G_Preferr

Capital Stock - Series G Preferred Stock Transactions - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

0 Months Ended

Mar. 12, 2013

Jan. 22, 2013

Jun. 26, 2014

29-May-14

Dec. 31, 2013

Mar. 31, 2013

Jun. 30, 2014

Mar. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Mar. 09, 2012

Sep. 30, 2013

Mar. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Mar. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Mar. 09, 2012

Mar. 31, 2014

Jun. 30, 2014

Mar. 31, 2014

Mar. 09, 2012

Jun. 30, 2014

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Directors

Co-Chairman, Chief Executive Officer, Chief Scientific Officer and Director [Member]

Common Stock [Member]

Common Stock [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

AR Partners, LLC [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Common Stock [Member]

Common Stock [Member]

Co-Chairman, Chief Executive Officer, Chief Scientific Officer and Director [Member]

Changes In Equity And Comprehensive Income Line Items [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock sold

5,000,000

10,125,000

5,500,000

3,333,333

'

'

'

'

17,033,000

37,991,000

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

Issuance price per share

$0.20

$0.20

'

'

'

'

'

$0.20

'

'

'

'

'

'

'

'

$0.20

'

'

'

'

'

'

$1

'

Total proceeds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

'

Convertible preferred stock, conversion price

'

'

'

'

$0.15

$0.20

$0.07

'

'

'

$0.40

$0.30

$0.37

$0.25

$0.30

'

'

'

'

'

'

'

'

'

'

Conversion ratio for each share

'

'

'

'

'

'

'

'

'

'

2.5

3.28

2.67

3.9289

3.291

'

'

'

'

'

'

'

'

'

'

Convertible Redeemable Preferred stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

5,000,000

'

'

'

'

1,000,000

'

'

'

'

'

Number of directors to be nominated by preferred shareholders

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of independent directors out of directors to be nominated by preferred shareholders

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Legal costs

'

'

'

'

'

'

'

'

'

'

$59,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Redeemable Preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

5,000,000

'

'

'

'

'

'

'

'

'

'

Issuance price per share

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

$0.07

'

'

'

$0.15

$0.15

'

$0.18

$0.19

$0.22

'

'

Convertible shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

$0.10

Capital_Stock_2013_Securities_

Capital Stock - 2013 Securities Purchase Agreements for Common Stock - Additional Information (Detail) (USD $)	0 Months Ended			1 Months Ended		6 Months Ended
	Jul. 19, 2013	Mar. 12, 2013	Jan. 22, 2013	Jun. 26, 2014	29-May-14	Jun. 30, 2014	Jun. 30, 2013	Aug. 31, 2013	Jul. 31, 2013
Class Of Stock [Line Items]	'	'	'	'	'	'	'	'	'
Number of shares of common stock sold	'	5,000,000	10,125,000	5,500,000	3,333,333	'	'	'	'
Issuance price per share	'	$0.20	$0.20	'	'	'	'	'	'
Proceeds from sale of common stock	$2,377,000	$1,000,000	$2,025,000	$550,000	$500,000	$2,638,000	$3,289,000	'	'
Warrant, term	'	'5 years	'5 years	'	'	'	'	'	'
Percentage of Warrants to common stock purchased	'	50.00%	50.00%	'	'	'	'	'	'
Warrants outstanding convertible into common stock	'	2,500,000	5,062,500	'	'	7,762,500	9,462,500	'	'
Warrants exercisable price	'	0.2	0.2	'	'	'	'	0.25	0.15
Co-Chairman and Chief Executive Officer [Member]	'	'	'	'	'	'	'	'	'
Class Of Stock [Line Items]	'	'	'	'	'	'	'	'	'
Proceeds from sale of common stock	'	$100,000	'	'	'	'	'	'	'
Warrant, term	'	'5 years	'5 years	'	'	'	'	'	'
Warrants outstanding convertible into common stock	'	250,000	'	'	'	'	'	'	'

Capital_Stock_2013_S1_July_Reg

Capital Stock - 2013 S-1 July Registered Offering - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Jul. 19, 2013

Mar. 12, 2013

Jan. 22, 2013

Jun. 26, 2014

29-May-14

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Aug. 31, 2013

Jul. 31, 2013

Dec. 31, 2012

Jul. 19, 2013

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 12, 2013

Jan. 22, 2013

Jul. 19, 2013

Dec. 31, 2013

Jun. 16, 2014

Jul. 24, 2013

Dec. 31, 2013

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 11, 2014

Mar. 31, 2014

Jul. 31, 2013

Jul. 19, 2013

Jun. 11, 2014

Jun. 11, 2014

Oct. 24, 2013

Jul. 24, 2013

Jul. 19, 2013

Jul. 24, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 19, 2013

Dec. 31, 2013

Jul. 19, 2013

Dec. 31, 2013

Jul. 19, 2013

Dec. 31, 2013

Jul. 19, 2013

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Co-Chairman and Chief Executive Officer [Member]

Co-Chairman and Chief Executive Officer [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Units [Member]

Units [Member]

Units [Member]

Units [Member]

Units [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Units and Series B Warrants [Member]

Subscription Agreements [Member]

Co-Chairman and Chief Executive Officer [Member]

Company's Chief Scientific Officer [Member]

Subscription Agreements [Member]

Placement Agent Warrants [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Adjusted [Member]

Subscription Agreements [Member]

Co-Chairman and Chief Executive Officer [Member]

Co-Chairman and Chief Executive Officer [Member]

Company's Chief Scientific Officer [Member]

Company's Chief Scientific Officer [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Class Of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares/warrants included in units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

16,754,822

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

$0.00

'

'

'

'

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercisable price

'

0.2

0.2

'

'

'

'

'

'

0.25

0.15

'

0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.15

0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants issued

'

'

'

'

'

'

'

64,983,988

'

'

'

'

666,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

5,998,999

'

667,667

'

'

Proceeds from sale of units and warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,000,000

Number of units issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

16,754,822

'

5,998,999

667,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of agent fee on gross proceeds from Offering

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum amount of reimbursement payable to agent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

'

'

'

'

'

'

'

'

Percentage of agent warrants to purchase on units issued in offering

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, term

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'65 days

'

'

'

'

'

'

'

'

'

Percentage of Agent cash solicitation fee on gross proceeds

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Series B warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

Warrants exercise price

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

$0.15

'

'

$0.15

'

'

'

'

'

'

'

Expiration date of warrants

'

'

'

'

'

'

'

24-Oct-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24-Oct-13

24-Oct-13

'

'

'

'

'

'

'

'

'

'

Proceeds from sale of common stock

2,377,000

1,000,000

2,025,000

550,000

500,000

2,638,000

3,289,000

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

497,000

'

'

'

'

'

'

'

30,000

'

'

'

'

'

'

'

1,722,000

'

'

'

2,356,000

634,000

'

'

'

'

'

497,000

'

Number of warrants exercised

'

'

'

'

'

'

'

16,954,822

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

12,304,822

'

'

'

16,754,822

4,450,000

'

2,754,821

'

667,667

'

'

'

Adjusted exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds form warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

'

'

'

'

'

'

1,722,000

'

'

'

'

634,000

'

'

'

'

'

'

'

Proceeds from exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$497,000

'

'

'

'

'

'

'

$30,000

'

'

'

'

'

'

'

$1,722,000

'

'

'

$2,356,000

$634,000

'

'

'

'

'

$497,000

'

Number of shares of common stock sold

'

5,000,000

10,125,000

5,500,000

3,333,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expired unexercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,245,178

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

'

'

'

'

'

7,762,500

'

44,983,988

'

'

'

3,500,000

'

0

666,666

666,666

'

'

'

'

10,088,154

'

'

'

'

'

'

36,554,822

0

'

36,554,822

'

'

666,666

10,088,154

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for future issuance

'

'

'

'

'

0

'

37,888,154

37,888,154

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,554,822

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital_Stock_2014_Securities_

Capital Stock - 2014 Securities Purchase Agreements for Common Stock - Additional Information (Detail) (USD $)	0 Months Ended			1 Months Ended		6 Months Ended
	Jul. 19, 2013	Mar. 12, 2013	Jan. 22, 2013	Jun. 26, 2014	29-May-14	Jun. 30, 2014	Jun. 30, 2013
Class Of Stock [Line Items]	'	'	'	'	'	'	'
Number of shares of common stock sold	'	5,000,000	10,125,000	5,500,000	3,333,333	'	'
Common stock value per share	'	'	'	$0.10	$0.15	'	'
Proceeds from sale of common stock	$2,377,000	$1,000,000	$2,025,000	$550,000	$500,000	$2,638,000	$3,289,000
For cash, net of issuance costs of $178 in 2013 and $169 in 2014, shares	'	5,000,000	10,125,000	5,500,000	3,333,333	'	'

Capital_Stock_2014_Warrant_Exc

Capital Stock - 2014 Warrant Exchange Agreements - Additional Information (Detail)

0 Months Ended

0 Months Ended

0 Months Ended

Jun. 11, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Jun. 16, 2014

Jun. 30, 2014

Jun. 11, 2014

Mar. 31, 2014

Dec. 31, 2013

Jun. 11, 2014

Jun. 11, 2014

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Placement Agent Warrants [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Class Of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock issued for warrant exchange

44,665,783

'

'

'

'

'

'

'

12,105,784

'

'

'

'

'

12,105,784

Common stock reserved for future issuance

'

0

37,888,154

37,888,154

'

'

'

'

'

'

36,554,822

'

'

'

'

Warrants outstanding

'

7,762,500

'

44,983,988

3,500,000

0

666,666

666,666

10,088,154

0

'

36,554,822

36,554,822

666,666

10,088,154

Capital_Stock_2013_Lincoln_Par

Capital Stock - 2013 Lincoln Park Capital Fund, LLC Stock Purchase Agreement - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

Jul. 19, 2013

Mar. 12, 2013

Jan. 22, 2013

Jun. 26, 2014

29-May-14

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 11, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Common Stock Purchase Agreement [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Lincoln Park Capital Fund, LLC [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Limit One [Member]

Limit Two [Member]

Limit Three [Member]

Minimum [Member]

Class Of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential common stock value to be sold

'

'

'

'

'

$10,250,000

'

'

'

'

$10,250,000

'

'

'

'

'

'

Number of shares of common stock sold

'

5,000,000

10,125,000

5,500,000

3,333,333

'

'

'

'

9,866,666

1,666,666

3,000,000

8,200,000

'

'

'

'

Common stock sold

'

'

'

'

'

'

'

'

'

1,838,000

250,000

'

1,588,000

'

'

'

'

Cash fee paid for commitment to purchase additional shares

'

'

'

'

'

'

'

'

'

'

155,000

'

'

'

'

'

'

Proceeds from sale of common stock

2,377,000

1,000,000

2,025,000

550,000

500,000

'

2,638,000

3,289,000

'

'

'

484,000

1,588,000

'

'

'

'

Potential number of shares of common stock to be sold

'

'

'

'

'

'

'

'

10,133,334

'

'

'

'

'

'

'

'

Potential common stock value to be sold

'

'

'

'

'

'

'

'

8,412,000

'

'

'

'

'

'

'

'

Common shares authorized to purchase

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

300,000

400,000

'

Closing price of common stock

'

'

'

'

'

$0.21

'

'

'

'

'

'

'

'

'

'

$0.05

Common stock value under stock purchase agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$500,000

Capital_Stock_Aspire_Common_St

Capital Stock - Aspire Common Stock Purchase Agreement - Additional Information (Detail) (USD $)	0 Months Ended			1 Months Ended		6 Months Ended		0 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended
	Jul. 19, 2013	Mar. 12, 2013	Jan. 22, 2013	Jun. 26, 2014	29-May-14	Jun. 30, 2014	Jun. 30, 2013	Dec. 09, 2010	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2013
								Aspire Capital Fund, LLC [Member]	Aspire Capital Fund, LLC [Member]	Aspire Capital Fund, LLC [Member]	Aspire Capital Fund, LLC [Member]
								Common Stock Purchase Agreement [Member]	Common Stock Purchase Agreement [Member]	Registration Rights [Member]	Registration Rights [Member]
Class Of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Maximum commitment under stock purchase agreement	'	'	'	'	'	'	'	$25,000,000	'	'	'
Purchase agreement expired	'	'	'	'	'	'	'	'	31-Dec-13	'	'
Common stock purchase agreement period	'	'	'	'	'	'	'	'3 years	'	'	'
Number of shares of common stock sold	'	5,000,000	10,125,000	5,500,000	3,333,333	'	'	'	'	0	1,200,000
Proceeds from sale of common stock	$2,377,000	$1,000,000	$2,025,000	$550,000	$500,000	$2,638,000	$3,289,000	'	'	$0	$264,000

Capital_Stock_Summary_of_Share

Capital Stock - Summary of Shares of Common Stock Reserved for Future Issuance (Detail)	Jun. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Shares of common stock reserved for future issuance net	132,111,479
Options Outstanding [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Shares of common stock reserved for future issuance net	27,318,410
Options Available for Future Grant [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Shares of common stock reserved for future issuance net	8,396,333
Warrants [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Shares of common stock reserved for future issuance net	7,762,500
Convertible Preferred Stock [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Shares of common stock reserved for future issuance net	88,634,236

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Related Party Transactions [Abstract]	'	'	'	'
Related party rent expense	$41,000	$45,000	$81,000	$79,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Provision for income taxes	'	'	'	'

Stock_Options_and_Warrants_Sto

Stock Options and Warrants - Stock Options - Additional Information (Detail) (USD $)	6 Months Ended			6 Months Ended		6 Months Ended	12 Months Ended		6 Months Ended	12 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2006	Jun. 30, 2014	Dec. 31, 2010	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2009	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014
		2006 Plan [Member]	2006 Plan [Member]	2010 Plan [Member]	2010 Plan [Member]	Outside Plan [Member]	Outside Plan [Member]	Outside Plan [Member]	2006 Plan and 2010 Plan [Member]	2006 Plan and 2010 Plan [Member]	2006 Plan and 2010 Plan [Member]
											Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of options that may be granted	'	'	15,000,000	'	18,000,000	'	'	'	'	'	'
Expiry of options	'	'10 years	'	'10 years	'	'10 years	'	'	'	'	'10 years
Options granted to employees, directors and consultants	'	'	'	'	'	'	'	10,257,593	4,104,000	1,491,500	'
Options vesting terms	'	'	'	'	'	'50 months	'	'	'	'	'
Unrecognized compensation expense related to stock options	$1,562,000	'	'	'	'	'	'	'	'	'	'
Unrecognized compensation cost related to weighted-average period	'1 year 9 months 11 days	'	'	'	'	'	'	'	'	'	'

Stock_Options_and_Warrants_Sch

Stock Options and Warrants - Schedule of Total Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$374,000	$440,000	$721,000	$849,000
Cost of Sales [Member]	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	15,000	'	30,000	'
Research and Development [Member]	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	73,000	93,000	143,000	177,000
Selling and Marketing [Member]	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	12,000	10,000	23,000	19,000
General and Administrative [Member]	'	'	'	'
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$274,000	$337,000	$525,000	$653,000

Stock_Options_and_Warrants_Fai

Stock Options and Warrants - Fair Value of Stock Option Award, Weighted Average Assumptions (Detail) (Options Available for Future Grant [Member])	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Options Available for Future Grant [Member]	'	'	'	'
Significant assumptions (weighted average):	'	'	'	'
Risk-free interest rate at grant date	1.91%	0.95%	1.91%	0.95%
Expected stock price volatility	99.72%	118.34%	99.72%	118.34%
Expected dividend payout	0.00%	0.00%	0.00%	0.00%
Expected option life based on management's estimate	'6 years 1 month 6 days	'6 years 1 month 6 days	'6 years 1 month 6 days	'6 years 1 month 6 days

Stock_Options_and_Warrants_Sum

Stock Options and Warrants - Summary of Changes in Options Outstanding and Related Exercise Prices for Shares of Company's Common Stock Options Issued (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2009
2006 Plan and 2010 Plan [Member]	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Number of Shares, Outstanding, Beginning balance	16,028,400	15,122,900	'
Options granted to employees, directors and consultants	4,104,000	1,491,500	'
Number of Shares, Exercised	'	'	'
Number of Shares, Canceled or expired	-423,283	-586,000	'
Number of Shares, Outstanding, Ending balance	19,709,117	16,028,400	'
Number of Shares, Options vested and expected to vest Ending Balance	18,704,421	'	'
Number of Shares, Options exercisable Ending Balance	12,626,784	'	'
Weighted Average Exercise Price Per Share, Outstanding, Beginning balance	$1.12	$1.18	'
Weighted Average Exercise Price Per Share, Granted	$0.16	$0.26	'
Weighted Average Exercise Price Per Share, Exercised	'	'	'
Weighted Average Exercise Price Per Share, Canceled or expired	$0.72	$0.61	'
Weighted Average Exercise Price Per Share, vested and exercisable Ending balance	$0.93	$1.12	'
Weighted Average Exercise Price, Options vested or expected to vest Ending Balance	$0.97	'	'
Weighted Average Exercise Price, Options exercisable Ending Balance	$1.20	'	'
Weighted Average Remaining Contractual Term, Options Outstanding Ending Balance	'6 years 8 months 19 days	'	'
Weighted Average Remaining Contractual Term, Options vested or expected to vest Ending Balance	'6 years 6 months 26 days	'	'
Weighted Average Remaining Contractual Term, Options exercisable Ending Balance	'5 years 5 months 23 days	'	'
Outside Plan [Member]	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Number of Shares, Outstanding, Beginning balance	7,609,293	8,254,232	'
Options granted to employees, directors and consultants	'	'	10,257,593
Number of Shares, Exercised	'	'	'
Number of Shares, Canceled or expired	'	-644,939	'
Number of Shares, Outstanding, Ending balance	7,609,293	7,609,293	'
Number of Shares, Options vested and expected to vest Ending Balance	'	'	'
Number of Shares, Options exercisable Ending Balance	'	'	'
Weighted Average Exercise Price Per Share, Outstanding, Beginning balance	$0.62	$0.65	'
Weighted Average Exercise Price Per Share, Granted	'	'	'
Weighted Average Exercise Price Per Share, Exercised	'	'	'
Weighted Average Exercise Price Per Share, Canceled or expired	'	$1	'
Weighted Average Exercise Price Per Share, vested and exercisable Ending balance	$0.62	$0.62	'
Weighted Average Exercise Price, Options vested or expected to vest Ending Balance	'	'	'
Weighted Average Exercise Price, Options exercisable Ending Balance	'	'	'
Weighted Average Remaining Contractual Term, Options Outstanding Ending Balance	'5 years 4 months 10 days	'	'
Weighted Average Remaining Contractual Term, Options vested or expected to vest Ending Balance	'5 years 4 months 10 days	'	'
Weighted Average Remaining Contractual Term, Options exercisable Ending Balance	'5 years 4 months 10 days	'	'
Aggregate Intrinsic Value, Options outstanding, Ending balance	'	'	'
Aggregate Intrinsic Value, Options vested or expected to vest Ending Balance	'	'	'
Aggregate Intrinsic Value, Options exercisable Ending Balance	'	'	'

Stock_Options_and_Warrants_Sum1

Stock Options and Warrants - Summary of Changes in Restricted Stock Award Activity (Detail) (Under 2006B PlanB and 2010 Plan, USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Under 2006B PlanB and 2010 Plan	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Number of Shares, Unvested, Beginning balance	145,000	335,000
Number of Shares, Granted	716,500	961,000
Number of Shares, Vested	-388,750	-1,029,750
Number of Shares, Forfeited	'	-121,250
Number of Shares, Unvested, Ending balance	472,750	145,000
Weighted Average Grant Date Fair Value, Unvested, Beginning balance	$0.23	$0.32
Weighted Average Grant Date Fair Value, Granted	$0.21	$0.24
Weighted Average Grant Date Fair Value, Vested	$0.23	$0.27
Weighted Average Grant Date Fair Value, Forfeited	'	$0.25
Weighted Average Grant Date Fair Value, Unvested, Ending balance	$0.20	$0.23

Stock_Options_and_Warrants_Res

Stock Options and Warrants - Restricted Stock Awards - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$374,000	$440,000	$721,000	$849,000
Unrecognized compensation cost related to weighted-average period	'	'	'1 year 9 months 11 days	'
Restricted Stock [Member]	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Grant-date fair value of restricted stock awards	'	'	91,000	188,000
Stock-based compensation expense	46,000	69,000	85,000	137,000
Unrecognized compensation costs	$84,000	'	$84,000	'
Unrecognized compensation cost related to weighted-average period	'	'	'6 months 26 days	'

Stock_Options_and_Warrants_War

Stock Options and Warrants - Warrants Issued with Preferred Stock - Additional Information (Detail)

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Jun. 30, 2014

Aug. 31, 2013

Jul. 31, 2013

Mar. 12, 2013

Jan. 22, 2013

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2008

Jul. 24, 2013

Dec. 31, 2013

Dec. 31, 2008

Dec. 31, 2008

12-May-08

Dec. 31, 2013

Dec. 31, 2008

Jul. 24, 2013

Dec. 31, 2008

Jun. 30, 2014

Dec. 31, 2013

Skin Care Marketing [Member]

Skin Care Marketing [Member]

Skin Care Marketing [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Skin Care Marketing [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants in each unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

2

'

'

Number of shares in each unit

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

1

'

1

'

'

'

'

Warrants outstanding

44,983,988

7,762,500

'

'

'

'

3,500,000

200,000

200,000

200,000

'

'

'

0

2,000,000

'

'

'

'

'

1,100,000

'

0

Warrants exercisable price

'

'

0.25

0.15

0.2

0.2

'

'

'

'

'

'

0.15

'

'

'

0.5

'

'

0.15

'

0.25

'

Expiration date of warrants

24-Oct-13

'

'

'

'

'

'

'

'

'

31-Jan-13

'

'

'

'

'

'

31-Jul-13

'

'

'

'

'

Stock_Options_and_Warrants_War1

Stock Options and Warrants - Warrants Issued with Common Stock - Additional Information (Detail)	0 Months Ended		1 Months Ended
	Mar. 12, 2013	Jan. 22, 2013	Jun. 26, 2014	29-May-14	Jun. 30, 2014	Aug. 31, 2013	Jul. 31, 2013	Jun. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Number of shares of common stock sold	5,000,000	10,125,000	5,500,000	3,333,333	'	'	'	'
Warrant to purchase common stock	2,500,000	5,062,500	'	'	7,762,500	'	'	9,462,500
Warrants exercisable price	0.2	0.2	'	'	'	0.25	0.15	'
Warrants, term	'5 years	'5 years	'	'	'	'	'	'
Co-Chairman and Chief Executive Officer [Member]	'	'	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Warrant to purchase common stock	250,000	'	'	'	'	'	'	'
Warrants, term	'5 years	'5 years	'	'	'	'	'	'

Stock_Options_and_Warrants_201

Stock Options and Warrants - 2013 S-1 July Registered Offering - Additional Information (Detail)

6 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Mar. 12, 2013

Jan. 22, 2013

Jul. 24, 2013

Jul. 24, 2013

Dec. 31, 2013

Jul. 24, 2013

Jul. 24, 2013

12-May-08

Common Stock [Member]

Units [Member]

Units [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares/warrants included in units

'

'

'

'

'

'

20,000,000

'

'

20,000,000

'

'

Warrants exercisable price

'

'

0.25

0.15

0.2

0.2

'

'

'

0.15

0.15

0.5

Number of units issued

'

'

'

'

'

'

'

20,000,000

16,754,822

'

'

400,000

Number of warrants issued

'

64,983,988

'

'

'

'

'

'

'

'

20,000,000

'

Stock_Options_and_Warrants_2011

Stock Options and Warrants - 2013 S-1 July Registered Offering - July 19, 2013 - Additional Information (Detail) (USD $)	0 Months Ended			6 Months Ended	12 Months Ended	0 Months Ended		1 Months Ended	0 Months Ended
	Jul. 19, 2013	Mar. 12, 2013	Jan. 22, 2013	Jun. 30, 2014	Dec. 31, 2013	Jul. 24, 2013	Jul. 19, 2013	Jul. 24, 2013	Jul. 19, 2013
						Series B Warrants [Member]	Series B Warrants [Member]	Series B Warrants [Member]	Placement Agent Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'
Percentage of agent fee on gross proceeds from Offering	5.00%	'	'	'	'	'	'	'	'
Warrants initial exercise price	'	'	'	'	'	$0.15	$0.15	'	$0.15
Number of warrants issued	'	'	'	'	64,983,988	'	'	'	666,666
Percentage of agent warrants to purchase on units issued in offering	'	'	'	'	'	'	'	'	5.00%
Maximum amount of reimbursement payable to agent	'	'	'	'	'	'	$75,000	'	'
Percentage of Agent cash solicitation fee on gross proceeds	5.00%	'	'	'	'	'	'	'	'
Warrants, term	'	'5 years	'5 years	'	'	'	'	'65 days	'5 years

Stock_Options_and_Warrants_2012

Stock Options and Warrants - 2013 S-1 July Registered Offering - Series B Warrants - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended	0 Months Ended		1 Months Ended
	Mar. 12, 2013	Jan. 22, 2013	Dec. 31, 2013	Jul. 24, 2013	Jul. 19, 2013	Jul. 24, 2013
				Series B Warrants [Member]	Series B Warrants [Member]	Series B Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'
Warrants initial exercise price	'	'	'	$0.15	$0.15	'
Closing bid price of common stock	'	'	'	80.00%	'	80.00%
Expiration date of warrants	'	'	24-Oct-13	24-Oct-13	24-Oct-13	'
Warrants, term	'5 years	'5 years	'	'	'	'65 days

Stock_Options_and_Warrants_2013

Stock Options and Warrants - 2013 S-1 July Registered Offering - Series A Warrants - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Closing price of common stock	$0.21
Warrant exercise price	$0.15
Stock price volatility	84.30%
Maximum [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Closing price of common stock	$0.15
U.S. Treasury Notes [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Risk free interest rate	1.55%
Series-A and Placement Agent Warrants [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Options and warrant expected term	'4 years 6 months 22 days

Stock_Options_and_Warrants_Fai1

Stock Options and Warrants - Fair Value of the Warrant Liabilities - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended	6 Months Ended
	Jul. 24, 2013	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Fair value of warrant liability in excess of proceeds	$1,390,000	'	'	'
Warrant liabilities	4,485,000	'	'	4,925,000
Change in fair value of warrant liability	'	1,271,000	1,894,000	'
Placement Agent Warrants [Member]	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Fair Value of Warrant Issued	115,000	'	'	'
Series A Warrants [Member]	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Fair Value of Warrant Issued	1,725,000	'	'	'
Series B Warrants [Member]	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Fair Value of Warrant Issued	$2,645,000	'	'	'

Stock_Options_and_Warrants_Ser

Stock Options and Warrants - Series A and B Warrant Exercises - Additional Information (Detail) (USD $)

6 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Mar. 12, 2013

Jan. 22, 2013

Oct. 24, 2013

Jul. 24, 2013

Jul. 19, 2013

Dec. 31, 2013

Jul. 24, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

12-May-08

Dec. 31, 2013

Jul. 24, 2013

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Units [Member]

Units [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Co-Chairman and Chief Executive Officer [Member]

Company's Chief Scientific Officer [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of warrants

'

'

'

'

'

'

$1,722,000

'

'

$2,356,000

'

'

$30,000

'

'

'

$497,000

$497,000

'

'

'

Number of warrants exercised

'

16,954,822

'

'

'

'

12,304,822

'

'

16,754,822

'

'

200,000

'

2,754,821

667,667

'

'

'

'

'

Expiration date of warrants

'

24-Oct-13

'

'

'

'

'

24-Oct-13

24-Oct-13

'

'

'

'

'

'

'

'

'

'

31-Jul-13

'

Number of units issued

'

'

'

'

'

'

'

'

'

'

20,000,000

16,754,822

'

'

'

'

'

'

400,000

'

'

Proceeds from exercise of warrants

'

'

'

'

'

'

$1,722,000

'

'

$2,356,000

'

'

$30,000

'

'

'

$497,000

$497,000

'

'

'

Warrants exercisable price

'

'

0.25

0.15

0.2

0.2

'

'

'

'

'

'

'

0.15

'

'

'

'

0.5

'

0.15

From exercises of warrants, net of commissions of $98, shares

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

Stock_Options_and_Warrants_Ser1

Stock Options and Warrants - Series B Price Adjustment - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended	0 Months Ended				12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Oct. 24, 2013	Oct. 17, 2013	Jul. 24, 2013	Jul. 19, 2013	Dec. 31, 2013	Dec. 31, 2013
			Series B Warrants [Member]	Series B Warrants [Member]	Series B Warrants [Member]	Series B Warrants [Member]	Series B Warrants [Member]	Adjusted [Member]
								Series B Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Percentage of closing bid price for calculation of exercise price of warrants	'	'	'	20.00%	'	'	'	'
Closing bid price	'	'	'	$0.18	'	'	'	'
Adjusted exercise price	'	'	$0.15	'	'	'	'	'
Number of warrants exercised	'	16,954,822	12,304,822	'	'	'	16,754,822	4,450,000
Proceeds from exercise of warrants	'	'	$1,722,000	'	'	'	$2,356,000	$634,000
Warrants initial exercise price	'	'	'	'	$0.15	$0.15	'	$0.15
Warrants expired unexercised	'	'	3,245,178	'	'	'	'	'

Stock_Options_and_Warrants_2014

Stock Options and Warrants - 2014 Warrant Exchange Agreements - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Jun. 11, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Jun. 16, 2014

Jun. 30, 2014

Jun. 11, 2014

Mar. 31, 2014

Dec. 31, 2013

Jun. 11, 2014

Jun. 11, 2014

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Placement Agent Warrants [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock issued for warrant exchange

44,665,783

'

'

'

'

'

'

'

'

12,105,784

'

'

'

'

'

12,105,784

Common stock reserved for future issuance

'

0

0

37,888,154

37,888,154

'

'

'

'

'

'

36,554,822

'

'

'

'

Warrants outstanding

'

7,762,500

7,762,500

'

44,983,988

3,500,000

0

666,666

666,666

10,088,154

0

'

36,554,822

36,554,822

666,666

10,088,154

Warrant liability reclassified to equity upon warrant exchange

'

'

$3,031

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrant liability

'

1,271

1,894

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exchange inducement expense

'

3,445

3,445

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of common stock issued for warrant exchange

'

'

$6,428

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Options_and_Warrants_War2

Stock Options and Warrants - Warrants Issued with Other Financings - Additional Information (Detail) (USD $)

0 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

Mar. 12, 2013

Jan. 22, 2013

Jun. 30, 2014

Dec. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Sep. 30, 2011

Sep. 30, 2011

Dec. 31, 2011

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2011

Skin Care Marketing [Member]

Skin Care Marketing [Member]

Skin Care Marketing [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Warrants [Member]

YKA Loan [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Warrants [Member]

Tranches

Tranches

Tranches

Skin Care Marketing [Member]

Maximum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants issued

'

'

'

64,983,988

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

Warrants exercisable price

0.2

0.2

'

'

0.25

0.15

'

'

'

'

2

2

2

'

'

'

'

'

'

'

'

'

Expiration date of warrants

'

'

'

24-Oct-13

'

'

'

'

'

'

'

'

'

'

31-Aug-13

'

'

'

'

'

30-Sep-16

'

Number of tranches of common stock warrants issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

2

2

'

'

'

'

Number of shares which can be purchased by the exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

Strike prices

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.50

'

$1.50

'

'

'

'

Strike prices

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2

$2

'

'

'

'

'

Vesting over four quarters

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Four quarters

'

'

'

'

Warrants, term

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'5 years

Warrants outstanding

'

'

7,762,500

44,983,988

'

'

3,500,000

200,000

200,000

200,000

'

'

'

'

'

'

'

'

200,000

200,000

'

'

Stock_Options_and_Warrants_Sum2

Stock Options and Warrants - Summary of Outstanding Warrants Related to Warrant Transactions (Detail) (USD $)

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Aug. 31, 2013

Jul. 31, 2013

Mar. 12, 2013

Jan. 22, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Weighted Average [Member]

Weighted Average [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series A Common Stock [Member]

Series A Common Stock [Member]

Series B Common Stock [Member]

Series B Common Stock [Member]

Placement Agent [Member]

Placement Agent [Member]

YKA Loan [Member]

YKA Loan [Member]

Skin Care Marketing [Member]

Skin Care Marketing [Member]

Jan 2013 Financing [Member]

Jan 2013 Financing [Member]

Mar 2013 Financing [Member]

Mar 2013 Financing [Member]

Class Of Warrant Or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares, Outstanding, Beginning balance

44,983,988

3,500,000

'

'

'

'

'

'

'

'

'

'

'

1,600,000

'

300,000

36,554,822

'

'

'

666,666

'

'

1,400,000

200,000

200,000

5,062,500

'

2,500,000

'

Warrants, Issued

'

64,983,988

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,754,822

'

20,000,000

'

666,666

'

'

'

'

'

5,062,500

'

2,500,000

Warrants, Exchanged

-37,221,488

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-36,554,822

'

'

'

-666,666

'

'

'

'

'

'

'

'

'

Warrants, Exercised

'

-16,954,822

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-200,000

'

-16,754,822

'

'

'

'

'

'

'

'

'

'

Warrants, Forfeited/Cancelled

'

-6,545,178

'

'

'

'

'

'

'

'

'

'

'

-1,600,000

'

-300,000

'

'

'

-3,245,178

'

'

'

-1,400,000

'

'

'

'

'

'

Number of Shares, Outstanding, Ending balance

7,762,500

44,983,988

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,554,822

'

'

'

666,666

'

'

200,000

200,000

5,062,500

5,062,500

2,500,000

2,500,000

Weighted Average Exercise Price, Outstanding, Beginning balance

'

'

0.25

0.15

0.2

0.2

0.145

0.25

2

2

0.166

0.336

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price, Issued

'

'

'

'

'

'

'

$0.15

'

$0.20

'

$0.16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price, Exchanged

'

'

'

'

'

'

'

'

$0.15

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price, Exercised

'

'

'

'

'

'

'

$0.14

'

$0.15

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price, Forfeited/Cancelled

'

'

'

'

'

'

'

$0.15

'

$0.25

'

$0.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price, Outstanding, Ending balance

'

'

0.25

0.15

0.2

0.2

0.145

0.145

2

2

0.24

0.166

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

Mar. 12, 2013

Jan. 22, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jan. 02, 2013

Jul. 01, 2011

Sep. 30, 2011

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Sep. 30, 2011

Dec. 31, 2011

Jul. 31, 2012

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Oceanside [Member]

Frederick [Member]

Priestly Drive [Member]

Priestly Drive [Member]

Priestly Drive [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Customer [Member]

Customer [Member]

Customer [Member]

Customer [Member]

Other Customer [Member}

sqft

sqft

sqft

sqft

sqft

Tranches

Tranches

Tranches

Sales [Member]

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Current square feet of leased office and laboratory

'

'

'

'

'

'

'

'

'

'

'

8,215

'

'

'

'

'

'

'

'

'

'

'

'

Expiry of lease

'

'

'

'

'

'

'

'

'

'

'

'2016-08

'

'

'

'

'

'

'

'

'

'

'

'

Current base rent

'

'

'

'

'

'

'

'

'

'

'

$8,588

$11,032

$11,837

'

'

'

'

'

'

'

'

'

'

Percentage of increase in monthly base rent

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

3.00%

'

'

'

'

'

'

'

'

'

'

Area of manufacturing facility given on lease

'

'

'

'

'

'

'

'

'

'

'

'

5,520

'

9,848

8,199

'

'

'

'

'

'

'

'

Expiry of Lease

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-15

29-Feb-16

'

'

'

'

'

'

'

'

'

'

Expiry of lease additional

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

Initial square feet of leased office and laboratory

'

'

'

'

'

'

'

'

'

'

'

'

'

4,653

'

'

'

'

'

'

'

'

'

'

Initial monthly base rent

'

'

'

'

'

'

'

'

'

'

'

'

'

5,118

'

'

'

'

'

'

'

'

'

'

Rent expense

'

'

79,000

84,000

158,000

158,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of net revenues for Direct Sales generated from the proprietary mailings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

Percentage of net revenues for Referral Sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

Termination of the agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

Number of tranches of common stock warrants issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

2

2

'

Common stock warrants to be issued for the benefit of the third party marketing organization

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

Strike prices

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.50

'

'

'

'

'

$1.50

'

Strike prices

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2

'

'

'

'

$2

'

'

Commission percentage on direct sale

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18.00%

Percentage on net revenue derived from referral sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

Commission expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,000

$19,000

$23,000

$43,000

'

'

'

Warrants, term

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

Percentage of revenue

'

'

'

'

'

'

19.00%

14.00%

20.00%

15.00%

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Summary of Future Minimum Lease Payments Required under Operating Leases that Have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2014 (remaining six months)	$194
2015	397
2016	101
2017	3
Total	$695

Segments_and_Geographic_Inform2

Segments and Geographic Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
	Product
	Subsidiary
	Segment
Segment Reporting [Abstract]	'
Number reporting segments	3
Number of wholly-owned subsidiaries	2
Human cell culture products	130

Segments_and_Geographic_Inform3

Segments and Geographic Information - Revenues, Expenses and Operating Income (Loss) by Market Segment (Detail) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Revenues:	'	'	'	'	'
Total revenues	$1,588,000	$1,457,000	$3,237,000	$2,742,000	$6,147,000
Total operating income (loss)	-2,243,000	-2,190,000	-4,308,000	-3,904,000	'
Operating expenses:	'	'	'	'	'
Total operating expenses	3,831,000	3,647,000	7,545,000	6,646,000	'
Operating income (loss):	'	'	'	'	'
Total revenues	1,588,000	1,457,000	3,237,000	2,742,000	6,147,000
Total operating income (loss)	-2,243,000	-2,190,000	-4,308,000	-3,904,000	'
Cosmeceutical Market [Member]	'	'	'	'	'
Revenues:	'	'	'	'	'
Total revenues	746,000	709,000	1,549,000	1,359,000	'
Total operating income (loss)	-39,000	-29,000	-24,000	18,000	'
Operating expenses:	'	'	'	'	'
Total operating expenses	785,000	738,000	1,573,000	1,341,000	'
Operating income (loss):	'	'	'	'	'
Total revenues	746,000	709,000	1,549,000	1,359,000	'
Total operating income (loss)	-39,000	-29,000	-24,000	18,000	'
Biomedical Market [Member]	'	'	'	'	'
Revenues:	'	'	'	'	'
Total revenues	842,000	748,000	1,688,000	1,383,000	'
Total operating income (loss)	184,000	168,000	324,000	249,000	'
Operating expenses:	'	'	'	'	'
Total operating expenses	658,000	580,000	1,364,000	1,134,000	'
Operating income (loss):	'	'	'	'	'
Total revenues	842,000	748,000	1,688,000	1,383,000	'
Total operating income (loss)	184,000	168,000	324,000	249,000	'
Therapeutic Market [Member]	'	'	'	'	'
Revenues:	'	'	'	'	'
Total operating income (loss)	-2,388,000	-2,329,000	-4,608,000	-4,171,000	'
Operating expenses:	'	'	'	'	'
Total operating expenses	2,388,000	2,329,000	4,608,000	4,171,000	'
Operating income (loss):	'	'	'	'	'
Total operating income (loss)	($2,388,000)	($2,329,000)	($4,608,000)	($4,171,000)	'

Segments_and_Geographic_Inform4

Segments and Geographic Information - Summary of Significant Revenues in Following Regions (Detail) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	$1,588,000	$1,457,000	$3,237,000	$2,742,000	$6,147,000
North America [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	1,318,000	1,064,000	2,667,000	2,082,000	'
Asia [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	162,000	294,000	340,000	421,000	'
Europe [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	101,000	77,000	210,000	188,000	'
All Other Regions [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	$7,000	$22,000	$20,000	$51,000	'

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (USD $)	0 Months Ended			1 Months Ended		6 Months Ended		0 Months Ended
	Jul. 19, 2013	Mar. 12, 2013	Jan. 22, 2013	Jun. 26, 2014	29-May-14	Jun. 30, 2014	Jun. 30, 2013	Aug. 06, 2014
								Securities Purchase Agreement
								Subsequent Event
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'
Number of shares of common stock sold	'	5,000,000	10,125,000	5,500,000	3,333,333	'	'	6,000,000
Convertible shares of common stock	'	'	'	'	'	'	'	$0.10
Proceeds from issuance of common stock	$2,377,000	$1,000,000	$2,025,000	$550,000	$500,000	$2,638,000	$3,289,000	$600,000